胰腺癌临床试验导航 | 海外癌症临床试验导航

正在招募 Phase 3

NCI NCT02757859 / NCI-2016-00588

High Volume Washing of the Abdomen in Increasing Survival After Surgery in Patients with Pancreatic Cancer That Can Be Removed by Surgery

AI 简述这是一项III期试验，研究高容量腹腔冲洗用于胰腺癌手术后的生存情况。

?

适用疾病: Periampullary Adenocarcinoma；Acinar Cell Carcinoma；Cholangiocarcinoma
干预: 未列出
地点: United States
申办方: Thomas Jefferson University Hospital

正在招募 Phase 3

NCI NCT03257033 / NCI-2018-01348

Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC

AI 简述这是一项III期试验，比较动脉内吉西他滨与静脉吉西他滨联合白蛋白紫杉醇用于局部晚期胰腺癌。

?

适用疾病: Stage II Pancreatic Cancer；Stage III Pancreatic Cancer；Locally Advanced Unresectable Pancreatic Adenocarcinoma
干预: 未列出
地点: United States
申办方: RenovoRx

正在招募 Phase 2, Phase 3

NCI NCT06367972 / NCI-2024-03278

Local Consolidative Therapy to Extend the Efficacy of Systemic Therapy in Oligoprogressive Metastatic Cancer, EXTEND-OP Trial

AI 简述这是一项II/III期试验，研究局部巩固治疗联合系统治疗用于寡进展转移性癌症，在美国开展。

?

适用疾病: Metastatic Urothelial Cancer；Metastatic Malignant Solid Tumor；Stage IV Gastric (Stomach) Cancer
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

正在招募 Phase 3

NCI NCT06593431 / NCI-2024-07461

Comparing the Effect of Local Therapy (MDT) in Combination with Systemic Therapy to Systemic Therapy Alone on Outcomes in Patients with Oligometastatic Pancreatic Cancer, EXPAND Trial

AI 简述这是一项III期试验，比较局部治疗联合全身治疗与单独全身治疗用于寡转移胰腺导管腺癌。

?

适用疾病: Oligometastatic Pancreatic Ductal Adenocarcinoma
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

正在招募 Phase 3

NCI NCT06958328 / NCI-2025-01624

Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer

AI 简述这是一项III期试验，测试高剂量放疗用于局部晚期胰腺癌，在美国和加拿大开展。

?

适用疾病: Stage II Pancreatic Cancer；Stage III Pancreatic Cancer；Stage IV Pancreatic Cancer
干预: 未列出
地点: United States，Canada
申办方: NRG Oncology

正在招募 Phase 3

NCI NCT06998940 / NCI-2025-03014

Studying Chemotherapy with or without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations

AI 简述这是一项III期试验，研究化疗联合或不联合帕尼单抗用于胰腺癌，在美国开展。

?

适用疾病: Stage II Pancreatic Cancer；Stage III Pancreatic Cancer；Stage IV Pancreatic Cancer
干预: 未列出
地点: United States
申办方: SWOG

正在招募 Phase 3

NCI NCT06362395 / NCI-2025-05948

Ultra-high Dose Radiation for Liver Metastasis Using MR-guided TReatment With Stereotactic Ablative Single-fraction

AI 简述这是一项III期试验，研究超高剂量立体定向放疗用于肝转移，在美国开展。

?

适用疾病: Non-Small Cell Lung Cancer；Head and Neck Squamous Cell Carcinoma；Cervical Squamous Cell Cancer
干预: 未列出
地点: United States
申办方: Toronto Western Hospital

正在招募 Phase 3 药物

ClinicalTrials.gov / NCI NCT01954992 / NCI-2013-02181

Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer

AI 简述这是一项3期试验，比较Glufosfamide与5-FU用于二线转移性胰腺癌。

?

适用疾病: Metastatic Pancreatic Adenocarcinoma；Stage IV Pancreatic Cancer；Recurrent Pancreatic Carcinoma
干预: Glufosfamide，Fluorouracil
地点: United States
申办方: Eleison Pharmaceuticals LLC.

正在招募 Phase 3 药物

ClinicalTrials.gov NCT04969731

Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer

AI 简述这是一项III期试验，研究Immuncell-LC联合吉西他滨用于可切除胰腺导管腺癌，在韩国开展。

?

适用疾病: Pancreatic Ductal Adenocarcinoma
干预: Immuncell-LC，Gemcitabine
地点: South Korea
申办方: GC Cell Corporation

正在招募 Phase 2, Phase 3 药物其他

ClinicalTrials.gov / NCI NCT05254171 / NCI-2023-01656

Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer

AI 简述这是一项II/III期试验，研究白蛋白紫杉醇和吉西他滨加或不加SBP-101用于胰腺癌。

?

适用疾病: Pancreatic Cancer Metastatic；Pancreatic Ductal Adenocarcinoma；Pancreatic Cancer Stage IV
干预: SBP-101，Nab-paclitaxel，Gemcitabine，Placebo
地点: United States，Australia，Austria，Belgium 等 6 个
申办方: Panbela Therapeutics, Inc.

正在招募 Phase 2, Phase 3 药物

ClinicalTrials.gov NCT05268692

Neoadjuvant Chemotherapy for Pancreatic Cancer Followed by GS and GnP

AI 简述这是一项II/III期试验，比较GS方案与GnP方案用于胰腺癌新辅助化疗。

?

适用疾病: Pancreatic Adenocarcinoma
干预: GS，GnP
地点: Japan
申办方: Kochi University

正在招募 Phase 3 药物

ClinicalTrials.gov / NCI NCT05477576 / NCI-2022-06406

Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

AI 简述这是一项3期试验，比较RYZ101与标准治疗用于177Lu-SSA治疗后进展的SSTR+胃肠胰神经内分泌肿瘤，在美国、比利时等地开展。

?

适用疾病: GEP-NET；Gastroenteropancreatic Neuroendocrine Tumor；Gastroenteropancreatic Neuroendocrine Tumor Disease
干预: RYZ101，Everolimus，Sunitinib，Octreotide
地点: United States，Belgium，Brazil，Canada 等 4 个
申办方: RayzeBio, Inc.

正在招募 Phase 3 药物

ClinicalTrials.gov / NCI NCT05482516 / NCI-2023-01487

Evaluating Novel Therapies in ctDNA Positive GI Cancers

AI 简述这是一项3期试验，评估Atezolizumab联合贝伐珠单抗用于ctDNA阳性胃肠癌，包括结肠、直肠、胃癌等，在美国开展。

?

适用疾病: Colon Adenocarcinoma；Rectal Adenocarcinoma；Gastric Adenocarcinoma
干预: Atezolizumab，Bevacizumab
地点: United States
申办方: Georgetown University

正在招募 Phase 2, Phase 3 药物

ClinicalTrials.gov / NCI NCT06079346 / NCI-2024-03451

A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer

AI 简述这是一项II/III期试验，研究OT-101联合mFOLFIRINOX用于晚期不可切除或转移性胰腺癌。

?

适用疾病: Pancreatic Ductal Adenocarcinoma；Stage II Pancreatic Cancer；Stage III Pancreatic Cancer
干预: OT-101，mFOLFIRINOX
地点: United States
申办方: Oncotelic Inc.

正在招募 Phase 3 手术/操作

ClinicalTrials.gov NCT06391892

Liquid Biopsy (ctDNA) Guided Treatment in Localized Pancreatic Cancer: Neoadjuvant CTX vs. Upfront Surgery

AI 简述这是一项III期试验，比较新辅助化疗与直接手术用于局部胰腺癌，在奥地利开展。

?

适用疾病: Pancreatic Cancer；Circulating Tumor Cell；Predictive Cancer Model
干预: Neoadjuvant chemotherapy instead of upfront surgery，Upfront surgery
地点: Austria
申办方: Elisabethinen Hospital

正在招募 Phase 3 药物

ClinicalTrials.gov NCT06714604

Standard or Prolonged Neoadjuvant Chemotherapy Before Surgery for BR/LAPC

AI 简述这是一项III期试验，比较标准或延长新辅助化疗用于交界可切除/局部晚期胰腺癌。

?

适用疾病: Locally Advanced Pancreatic Adenocarcinoma；Borderline Resectable Pancreatic Carcinoma；Pancreas Cancer
干预: FOLFIRINOX or gemcitabine-nab-paclitaxel，FOLFIRINOX or gemcitabine-nab-paclitaxel
地点: Sweden
申办方: Sahlgrenska University Hospital

正在招募 Phase 3 药物

ClinicalTrials.gov NCT06897644

Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanced Pancreatic Cancer.

AI 简述这是一项III期试验，比较吉西他滨+白蛋白紫杉醇与改良FOLFIRINOX作为晚期胰腺癌的一线化疗。

?

适用疾病: Pancreatic Adenocarcinoma Advanced or Metastatic
干预: Oxaliplatin，Irinotecan (CPT-11)，Leucovorin，5-FU (5-fluorouracil)
地点: Italy
申办方: Gruppo Oncologico del Nord-Ovest

正在招募 Phase 3 药物手术/操作

ClinicalTrials.gov NCT07081360

Neoadjuvant vs Upfront Surgery for Resectable Pancreatic Cancer and Periampullary Cancer

AI 简述这是一项III期试验，比较新辅助化疗与直接手术用于可切除胰腺癌和壶腹周围癌，在埃及开展。

?

适用疾病: Pancreas Cancer；Periampullary Cancer；Periampullary Carcinoma Resectable
干预: Neoadjuvant chemotherapy，Upfront Surgery Group
地点: Egypt
申办方: Minia University

正在招募 Phase 3 药物手术/操作

ClinicalTrials.gov NCT07155525

Tissue Adhesive Glue Modified Cyanoacrylate (Glubran® 2) in Soft Pancreas

AI 简述这是一项III期试验，比较组织粘连胶改良氰基丙烯酸酯与标准胰肠吻合术用于胰腺癌、壶腹周围癌等。

?

适用疾病: Pancreatic Cancer；Periampullary Cancer；Duodenal Cancer
干预: Pancreaticojejunostomy with Modified N-Butyl-2-Cyanoacrylate (Glubran® 2)，Standard(duct-to-mucosa) Pancreaticojejunostomy
地点: Egypt
申办方: Minia University

正在招募 Phase 3 药物

ClinicalTrials.gov / NCI NCT07252232 / NCI-2026-00629

Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

AI 简述这是一项III期试验，研究daraxonrasib用于切除的胰腺导管腺癌，于美国、法国、意大利、日本等地开展。

?

适用疾病: Pancreatic Cancer；PDAC；PDAC - Pancreatic Ductal Adenocarcinoma
干预: daraxonrasib
地点: United States，France，Italy，Japan 等 3 个
申办方: Revolution Medicines, Inc.

正在招募 Phase 3 药物

ClinicalTrials.gov / NCI NCT07409272 / NCI-2026-01294

A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer

AI 简述这是一项III期试验，研究Setidegrasib联合化疗用于胰腺癌，在美国、日本等地开展。

?

适用疾病: Pancreatic Cancer；Metastatic Pancreatic Cancer；Metastatic Pancreatic Adenocarcinoma
干预: Setidegrasib，Oxaliplatin，Leucovorin，Irinotecan
地点: United States，Japan
申办方: Astellas Pharma Global Development, Inc.

正在招募 Phase 2, Phase 3 药物

ClinicalTrials.gov / NCI NCT07490301 / NCI-2026-02259

A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma

AI 简述这是一项II/III期试验，在美国、澳大利亚、以色列、日本等地开展，研究Telisotuzumab adizutecan联合FOLFOX用于一线转移性胰腺导管腺癌。

?

适用疾病: Metastatic Pancreatic Ductal Adenocarcinoma；PDAC；Stage II Pancreatic Cancer
干预: Telisotuzumab adizutecan，Fluorouracil，Folinic acid/ Leucovorina，Oxaliplatin
地点: United States，Australia，Israel，Japan 等 3 个
申办方: AbbVie

正在招募 Phase 3 药物

ClinicalTrials.gov / NCI NCT07491445 / NCI-2026-03710

Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

AI 简述这是一项III期试验，在美国、日本等地开展，研究Daraxonrasib联合吉西他滨和白蛋白紫杉醇用于转移性胰腺腺癌的一线治疗。

?

适用疾病: Pancreatic Cancer；Pancreatic Cancer Metastatic；PDAC
干预: daraxonrasib，gemcitabine，nab-paclitaxel
地点: United States，Japan
申办方: Revolution Medicines, Inc.

正在招募 Phase 3 药物

ClinicalTrials.gov / NCI NCT07522073 / NCI-2026-04028

A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma

AI 简述这是一项III期试验，研究INCB161734联合化疗用于KRAS G12D突变的转移性胰腺癌。

?

适用疾病: Solid Tumors；Stage IV Pancreatic Cancer；Metastatic Pancreatic Adenocarcinoma
干预: INCB161734，Placebo，Investigator's choice of chemotherapy
地点: United States，Australia，Austria，Belgium 等 16 个
申办方: Incyte Corporation

正在招募 Phase 3 药物

ClinicalTrials.gov / NCI NCT07562152 / NCI-2026-03937

Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

AI 简述这是一项III期试验，研究Atebimetinib联合GnP用于转移性胰腺导管腺癌一线治疗，在美国等地开展。

?

适用疾病: Pancreatic Cancer；Pancreatic Cancer Metastatic；PDAC
干预: Atebimetinib，GnP，mGnP
地点: United States，Australia
申办方: Immuneering Corporation

正在招募 Phase 3 药物

ClinicalTrials.gov / NCI NCT07621718 / NCI-2026-04342

Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )

AI 简述这是一项III期试验，研究Zoldonrasib联合化疗对比安慰剂联合化疗一线治疗KRAS G12D突变转移性胰腺癌，在美国开展。

?

适用疾病: Pancreatic Cancer；Pancreatic Cancer Metastatic；PDAC
干预: Zoldonrasib，Placebo，Oxaliplatin，Leucovorin (Calcium Folinate)
地点: United States
申办方: Revolution Medicines, Inc.

正在招募 Phase 1, Phase 2

NCI NCT03018405 / NCI-2017-00722

A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications

AI 简述这是一项I/II期试验，研究多种肿瘤适应症的药物。

?

适用疾病: Metastatic Urothelial Cancer；Advanced Malignant Solid Tumor；Refractory Acute Myeloid Leukemia (AML)
干预: 未列出
地点: United States
申办方: Celyad Oncology SA

正在招募 Phase 1, Phase 2

NCI NCT02843945 / NCI-2017-01570

Initial Feasibility Study to Treat Borderline Resectable Pancreatic Cancer With a Planar LDR Source

AI 简述这是一项I/II期试验，在美国开展，研究平面低剂量率放射源用于交界可切除胰腺癌。

?

适用疾病: Resectable Pancreatic Carcinoma；Stage III Pancreatic Cancer；Pancreatic Adenocarcinoma
干预: 未列出
地点: United States
申办方: CivaTech Oncology

正在招募 Phase 2

NCI NCT01676259 / NCI-2018-00398

A Phase 2 Study of siG12D LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer

AI 简述这是一项II期试验，研究siG12D LODER联合化疗用于局部晚期胰腺癌。

?

适用疾病: Stage III Pancreatic Cancer；Locally Advanced Pancreatic Ductal Adenocarcinoma；Borderline Resectable Pancreatic Carcinoma
干预: 未列出
地点: United States
申办方: Silenseed Ltd

正在招募 Phase 2

NCI NCT03634332 / NCI-2019-04731

Second-line Study of PEGPH20 and Pembro for HA High Metastatic PDAC

AI 简述这是一项II期试验，研究PEGPH20联合pembrolizumab用于透明质酸高表达的转移性胰腺导管腺癌。

?

适用疾病: Stage IV Pancreatic Cancer；Metastatic Pancreatic Ductal Adenocarcinoma
干预: 未列出
地点: United States
申办方: Pancreatic Cancer Research Team

正在招募 Phase 2

NCI NCT03935893 / NCI-2019-06773

Cell Therapy for the Treatment of Locally Advanced, Metastatic, or Recurrent Solid Cancers

AI 简述这是一项II期试验，研究细胞疗法用于局部晚期、转移性或复发性实体瘤，在美国开展。

?

适用疾病: Recurrent Merkel Cell Cancer；Recurrent Malignant Solid Tumor；Metastatic Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: University of Pittsburgh Cancer Institute (UPCI)

正在招募 Phase 1, Phase 2

NCI NCT04092673 / NCI-2019-07863

Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies

AI 简述这是一项I/II期试验，研究eFT226用于晚期实体瘤。

?

适用疾病: Advanced Malignant Solid Tumor；Refractory Malignant Solid Tumor；Stage III Pancreatic Cancer
干预: 未列出
地点: United States
申办方: Effector Therapeutics

正在招募 Phase 2

NCI NCT04449549 / NCI-2020-04956

Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel

AI 简述这是一项II期试验，研究尼罗替尼和紫杉醇用于罕见肿瘤，在美国开展。

?

适用疾病: Lepidic Adenocarcinoma；Malignant Solid Tumor；Stage IV Anal Cancer
干预: 未列出
地点: United States
申办方: National Cancer Institute

正在招募 Phase 1, Phase 2

NCI NCT03526835 / NCI-2021-03548

A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究双特异性抗体MCLA-158用于晚期实体瘤。在美国、比利时、法国、荷兰等开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Unresectable Esophageal Carcinoma；Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Merus N.V.

正在招募 Phase 2

NCI NCT04924075 / NCI-2021-07165

Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

AI 简述这是一项II期试验，研究Belzutifan用于晚期嗜铬细胞瘤/副神经节瘤、胰腺神经内分泌肿瘤等，在美国开展。

?

适用疾病: Malignant Solid Tumor；Metastatic Paraganglioma；Locally Advanced Paraganglioma
干预: 未列出
地点: United States
申办方: Merck Sharp and Dohme LLC

正在招募 Phase 1, Phase 2

NCI NCT04939610 / NCI-2021-07632

A Study of 177Lu-FAP-2286 in Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究177Lu-FAP-2286用于晚期实体瘤。

?

适用疾病: Recurrent Malignant Solid Tumor；Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Novartis Pharmaceuticals Corporation

正在招募 Phase 1, Phase 2

NCI NCT05086692 / NCI-2022-02678

A Beta-only IL-2 ImmunoTherapY Study

AI 简述这是一项I/II期试验，研究MDNA11联合Pembrolizumab用于晚期实体瘤，在美、澳、加、爱等地开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Metastatic Lung Non-Squamous Non-Small Cell Carcinoma；Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Medicenna Therapeutics, Inc.

正在招募 Phase 1, Phase 2

NCI NCT05358379 / NCI-2022-04029

A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma

AI 简述这是一项I/II期试验，研究CYC140用于晚期实体瘤和淋巴瘤。

?

适用疾病: Recurrent Malignant Solid Tumor；Metastatic Malignant Solid Tumor；Peripheral T-Cell Lymphoma, Unclassifiable
干预: 未列出
地点: United States
申办方: Cyclacel Pharmaceuticals, Inc.

正在招募 Phase 1, Phase 2

NCI NCT05417594 / NCI-2022-05317

Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

AI 简述这是一项1/2期试验，研究AZD9574单药或联合其他抗癌药用于晚期实体瘤，在美国开展。

?

适用疾病: Recurrent Fallopian Tube Cancer；Recurrent Primary Peritoneal Cancer；Castration-Resistant Prostate Cancer
干预: 未列出
地点: United States
申办方: AstraZeneca Pharmaceuticals LP

正在招募 Phase 1, Phase 2

NCI NCT05394103 / NCI-2022-10300

Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究CDK7抑制剂Q901用于晚期实体瘤。

?

适用疾病: Advanced Malignant Solid Tumor；Castration-Resistant Prostate Cancer；Stage III Colorectal (Colon or Rectal) Cancer
干预: 未列出
地点: United States
申办方: Qurient Co., Ltd.

正在招募 Phase 1, Phase 2

NCI NCT05786924 / NCI-2023-03966

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

AI 简述这是一项I/II期试验，研究S241656用于RAS/MAPK突变阳性恶性肿瘤。在美、丹、港、日等地开展。

?

适用疾病: Recurrent Malignant Solid Tumor；Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Institut de Recherches Internationales Servier

正在招募 Phase 2

NCI NCT05969860 / NCI-2023-05420

At-Home Cancer Directed Therapy versus in Clinic for the Treatment of Patients with Advanced Cancer, Cancer CARE Beyond Walls

AI 简述这是一项II期试验，比较在家与在医院进行癌症治疗用于晚期癌症患者。

?

适用疾病: Advanced Malignant Solid Tumor；Advanced Head and Neck Cancer；Advanced Melanoma
干预: 未列出
地点: United States
申办方: Mayo Clinic in Florida

正在招募 Phase 1, Phase 2

NCI NCT05934539 / NCI-2023-05619

ALG.APV-527 First-in-human Study

AI 简述这是一项I/II期试验，研究ALG.APV-527用于转移性尿路上皮癌及晚期实体瘤，在美国开展。

?

适用疾病: Metastatic Urothelial Cancer；Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Aptevo Therapeutics

正在招募 Phase 1, Phase 2

NCI NCT05684965 / NCI-2023-06173

XTX301 in Patients With Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究XTX301用于晚期实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Locally Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Xilio Development, Inc.

正在招募 Phase 2

NCI NCT06101277 / NCI-2023-09052

Local Ablative Therapy for the Treatment of Oligo-progressive Gastrointestinal Cancers, The LIVELONG Trial

AI 简述这是一项II期试验，在美国研究局部消融疗法用于寡进展性胃肠道癌症。

?

适用疾病: Metastatic Digestive System Cancer；Stage IV Small Intestinal Adenocarcinoma；Stage IV Appendix Cancer
干预: 未列出
地点: United States
申办方: University of California Davis Comprehensive Cancer Center

正在招募 Phase 2

NCI NCT06015724 / NCI-2024-01588

Daratumumab in Combination with KRAS Vaccine and Nivolumab in Treating Refractory Pancreatic Ductal Cancer and Advanced Refractory Non-Small Cell Lung Cancer

AI 简述这是一项II期试验，在美国研究Daratumumab联合KRAS疫苗和Nivolumab用于难治性胰腺癌和晚期非小细胞肺癌。

?

适用疾病: Stage III Lung Cancer；Stage IV Lung Cancer；Refractory Non-Small Cell Lung Cancer
干预: 未列出
地点: United States
申办方: MedStar Georgetown University Hospital

正在招募 Phase 1, Phase 2

NCI NCT06385925 / NCI-2024-04303

A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

AI 简述这是一项I/II期试验，研究TSN1611用于KRAS G12D突变晚期实体瘤，在美国等地开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Locally Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Tyligand Pharmaceuticals (Suzhou) Limited

正在招募 Phase 1, Phase 2

NCI NCT06598371 / NCI-2024-07763

Genetically Engineered Tumor Infiltrating Lymphocytes (KSQ-004EX) for the Treatment of Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究基因工程肿瘤浸润淋巴细胞KSQ-004EX用于多种晚期实体瘤，在美国开展。

?

适用疾病: Advanced Malignant Solid Tumor；Stage III Head and Neck Squamous Cell Cancer；Stage IV Head and Neck Squamous Cell Cancer
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

正在招募 Phase 2

NCI NCT05604560 / NCI-2024-10239

Tislelizumab and SX-682 before Surgery for the Treatment of Newly Diagnosed and Resectable Pancreatic Cancer

AI 简述这是一项II期试验，研究Tislelizumab联合SX-682用于可切除胰腺癌术前治疗。

?

适用疾病: Resectable Pancreatic Adenocarcinoma
干预: 未列出
地点: United States
申办方: University of Texas Health Science Center at San Antonio

正在招募 Phase 2

NCI NCT06330064 / NCI-2025-00431

A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)

AI 简述这是一项II期试验，研究Ifinatamab deruxtecan用于复发或转移性实体瘤，在美国开展。

?

适用疾病: Recurrent Bladder Urothelial Cancer；Metastatic Malignant Solid Tumor；Recurrent Intrahepatic Bile Duct Cancer (Cholangiocarcinoma)
干预: 未列出
地点: United States
申办方: Daiichi Sankyo

正在招募 Phase 1, Phase 2

NCI NCT06736717 / NCI-2025-01331

Onvansertib in Combination with NALIRIFOX for the Treatment of Metastatic Pancreatic Cancer

AI 简述这是一项I/II期试验，研究Onvansertib联合NALIRIFOX治疗转移性胰腺癌。在美国开展。

?

适用疾病: Stage IV Pancreatic Cancer；Metastatic Pancreatic Adenocarcinoma
干预: 未列出
地点: United States
申办方: University of Kansas Cancer Center

正在招募 Phase 1, Phase 2

NCI NCT07064018 / NCI-2025-03409

Single Protein Encapsulated Doxorubicin for the Treatment of Advanced, Refractory or Relapsed Solid Tumor Malignancies

AI 简述这是一项I/II期试验，研究Spedox-6用于多种晚期实体瘤，在美国开展。

?

适用疾病: Recurrent Malignant Solid Tumor；Advanced Malignant Solid Tumor；Refractory Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: UC Irvine Health/Chao Family Comprehensive Cancer Center

正在招募 Phase 1, Phase 2

NCI NCT06956690 / NCI-2025-04298

A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors

AI 简述这是一项I/II期试验，在美国和澳大利亚研究ENV-501用于HER3表达实体瘤。

?

适用疾病: Recurrent Malignant Solid Tumor；Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Hummingbird Bioscience

正在招募 Phase 2

NCI NCT06953089 / NCI-2025-05085

DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors

AI 简述这是一项II期试验，研究DB-1311联合BNT327或DB-1305用于晚期转移性实体瘤，在美国开展。

?

适用疾病: Recurrent Malignant Solid Tumor；Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: DualityBio Inc.

正在招募 Phase 1, Phase 2

NCI NCT06885034 / NCI-2025-05982

A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed

AI 简述这是一项I/II期试验，研究GSK5764227单药或联合用于晚期胃肠癌。

?

适用疾病: Stage III Colon Cancer；Stage IV Colon Cancer；Stage III Rectal Cancer
干预: 未列出
地点: United States
申办方: GlaxoSmithKline

正在招募 Phase 1, Phase 2

NCI NCT06907043 / NCI-2025-06439

A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.

AI 简述这是一项I/II期试验，研究PARP1抑制剂EIK1004用于晚期实体瘤。

?

适用疾病: Recurrent Fallopian Tube Cancer；Recurrent Primary Peritoneal Cancer；Recurrent Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Eikon Therapeutics

正在招募 Phase 1, Phase 2

NCI NCT07205718 / NCI-2025-08225

A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors

AI 简述这是一项I/II期试验，研究TAK-188用于晚期或转移性实体瘤，在美国开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Metastatic Lung Non-Squamous Non-Small Cell Carcinoma；Stage III Lip and Oral Cavity Cancer
干预: 未列出
地点: United States
申办方: Takeda

正在招募 Phase 2

NCI NCT07283705 / NCI-2025-09221

BMS-986504 and Chemotherapy for the Treatment of Resectable, Locally Advanced, Unresectable, or Metastatic, MTAP-Deleted Pancreatic Ducal Adenocarcinoma

AI 简述这是一项II期试验，研究BMS-986504联合化疗用于MTAP缺失的胰腺导管腺癌。

?

适用疾病: Stage II Pancreatic Cancer；Stage III Pancreatic Cancer；Stage IV Pancreatic Cancer
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

正在招募 Phase 1, Phase 2

NCI NCT07145255 / NCI-2026-00044

Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors

AI 简述这是一项I/II期试验，在美国研究ADC用于多种晚期难治实体瘤。

?

适用疾病: Advanced Malignant Solid Tumor；Refractory Malignant Solid Tumor；Stage III Colorectal (Colon or Rectal) Cancer
干预: 未列出
地点: United States
申办方: mBrace Therapeutics

正在招募 Phase 2

NCI NCT07282912 / NCI-2026-03014

Sequential Cytoreductive Interventions for the Treatment of Patients with Metastatic Digestive System Adenocarcinoma with Undetectable ctDNA

AI 简述这是一项II期试验，比较标准治疗联合或不联合序贯减瘤干预用于转移性前肠腺癌且ctDNA阴性患者，在美国开展。

?

适用疾病: Stage IV Esophageal Adenocarcinoma；Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8；Stage IV Gastric (Stomach) Cancer
干预: 未列出
地点: United States
申办方: Yale University

正在招募 Phase 1, Phase 2

NCI NCT07186842 / NCI-2026-03238

A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9

AI 简述这是一项I/II期试验，研究BNT329用于晚期实体瘤（表达CA19-9）。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
干预: 未列出
地点: United States
申办方: BioNTech SE

正在招募 Phase 1, Phase 2

NCI NCT07446855 / NCI-2026-03698

Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours

AI 简述这是一项1/2期试验，研究AZD4956单药或联合用药用于晚期/转移性HRD实体瘤，在美国等地开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Locally Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: AstraZeneca Pharmaceuticals LP

正在招募 Phase 1, Phase 2

NCI NCT06914128 / NCI-2026-04077

A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors

AI 简述这是一项I/II期试验，研究PRMT5抑制剂BAY 3713372用于MTAP缺失的实体瘤。

?

适用疾病: Malignant Solid Tumor；Non-Small Cell Lung Cancer；Glioblastoma
干预: 未列出
地点: United States
申办方: Bayer Corporation

正在招募 Phase 2 生物制剂药物

ClinicalTrials.gov / NCI NCT01174121 / NCI-2019-00142

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

AI 简述这是一项II期试验，研究肿瘤浸润淋巴细胞联合Pembrolizumab用于转移性癌症。

?

适用疾病: Metastatic Colorectal Cancer；Metastatic Pancreatic Cancer；Metastatic Ovarian Cancer
干预: Pembrolizumab (Keytruda)，Fludarabine，Cyclophosphamide，Aldesleukin
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 2 药物手术/操作放疗

ClinicalTrials.gov / NCI NCT02598349 / NCI-2023-02644

Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the Pancreas

AI 简述这是一项II期试验，研究质子放疗联合卡培他滨用于不可切除胰腺癌，在美国开展。

?

适用疾病: Pancreatic Cancer；Stage III Pancreatic Cancer；Borderline Resectable Pancreatic Carcinoma
干预: Proton Radiation，Capecitabine，Surgical resection
地点: United States
申办方: Proton Collaborative Group

正在招募 Phase 1, Phase 2 生物制剂药物

ClinicalTrials.gov / NCI NCT02830724 / NCI-2018-03328

Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers

AI 简述这是一项I/II期试验，在美国开展，研究Anti-hCD70 CAR转导淋巴细胞用于表达CD70的胰腺癌、肾癌、乳腺癌、黑色素瘤、卵巢癌。

?

适用疾病: Pancreatic Cancer；Renal Cell Cancer；Breast Cancer
干预: Cyclophosphamide，Fludarabine，Aldesleukin，Anti-hCD70 CAR transduced PBL
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 2 药物手术/操作

ClinicalTrials.gov NCT03080974

Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma

AI 简述这是一项II期试验，研究Nivolumab联合不可逆电穿孔用于晚期胰腺癌。

?

适用疾病: Pancreatic Adenocarcinoma
干预: Nivolumab，Irreversible Electroporation
地点: United States
申办方: University of Louisville

正在招募 Phase 2 药物

ClinicalTrials.gov NCT03175224

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

AI 简述这是一项II期试验，研究APL-101用于c-Met外显子14跳跃突变的非小细胞肺癌和晚期实体瘤，在美国、澳大利亚等地开展。

?

适用疾病: Solid Tumors；Advanced Cancer；Renal Cancer
干预: APL-101 Oral Capsules
地点: United States，Australia，Canada，France 等 7 个
申办方: Apollomics Inc.

正在招募 Phase 1, Phase 2 生物制剂药物

ClinicalTrials.gov / NCI NCT03190941 / NCI-2018-03522

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients

AI 简述这是一项I/II期试验，研究输注靶向KRAS G12V的T细胞用于HLA-A*11:01阳性的胰腺癌、胃癌等患者。

?

适用疾病: Pancreatic Cancer；Gastric Cancer；Gastrointestinal Cancer
干预: Cyclophosphamide，Fludarabine，Anti-KRAS G12V mTCR PBL，Aldesleukin
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 2 药物放疗

ClinicalTrials.gov NCT03322995

Pancreatic Cancer Adaptive Neoadjuvant Chemotherapy Trial

AI 简述一项II期试验，研究新辅助化疗用于胰腺癌。

?

适用疾病: Pancreatic Cancer
干预: First-line Chemotherapy，Second-line Chemotherapy，Chemoradiation
地点: United States
申办方: Medical College of Wisconsin

正在招募 Phase 2 药物放疗

ClinicalTrials.gov NCT03492671

Testing the Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized Pancreatic Cancer

AI 简述这是一项II期试验，研究吉西他滨、白蛋白紫杉醇联合立体定向放疗用于可切除胰腺癌。

?

适用疾病: Pancreas Adenocarcinoma；Resectable Pancreatic Cancer
干预: Gemcitabine 1000 mg，nab-paclitaxel，Stereotactic Body Radiation Therapy
地点: United States
申办方: Loma Linda University

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT03556228 / NCI-2018-01333

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

AI 简述这是一项I/II期试验，研究VMD-928单药或联合Pembrolizumab用于TrkA过表达的实体瘤或淋巴瘤。

?

适用疾病: Head and Neck Carcinoma；Adenoid Cystic Carcinoma；Lung Cancer
干预: VMD-928 100 mg Tablet，VMD-928 Tablet and Pembrolizumab (200 mg)
地点: United States，Puerto Rico
申办方: VM Oncology, LLC

正在招募 Phase 1, Phase 2 联合产品药物

ClinicalTrials.gov NCT03579836

Evaluation of Safety and Efficacy in BEY1107 in Monotherapy Gemcitabine Combination in Patient with Pancreatic Cancer

AI 简述这是一项I/II期试验，研究BEY1107单药或联合吉西他滨用于局部晚期或转移性胰腺癌。

?

适用疾病: Locally Advanced or Metastatic Pancreatic Cancer
干预: BEY1107，Gemcitabine
地点: South Korea
申办方: BeyondBio Inc.

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT03608631 / NCI-2018-01441

iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation

AI 简述这是一项I/II期试验，研究携带KRAS G12D siRNA的间充质干细胞外泌体用于转移性胰腺癌。

?

适用疾病: KRAS NP_004976.2:p.G12D；Metastatic Pancreatic Adenocarcinoma；Pancreatic Ductal Adenocarcinoma
干预: Mesenchymal Stromal Cells-derived Exosomes with KRAS G12D siRNA
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 2 药物

ClinicalTrials.gov NCT03915678

Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors

AI 简述这是一项II期试验，研究Atezolizumab联合BDB001和放疗用于晚期实体瘤。

?

适用疾病: Solid Tumor, Adult；Pancreatic Cancer；Virus-associated Tumors
干预: Association atezolizumab + BDB001 + RT，Association atezolizumab + BDB001+ RT，Association atezolizumab + BDB001+ RT，Association atezolizumab + BDB001 + RT
地点: France
申办方: Institut Bergonié

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT03977233 / NCI-2019-03901

Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer

AI 简述这是一项II期试验，研究FOLFIRINOX用于非转移性胰腺导管腺癌的肿瘤亚型。在美国开展。

?

适用疾病: Pancreatic Ductal Adenocarcinoma (PDAC)；Cancer of Pancreas；Pancreatic Cancer, Adult
干预: Oxaliplatin，Leucovorin，Irinotecan Hydrochloride，5-FU
地点: United States
申办方: UNC Lineberger Comprehensive Cancer Center

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT04115163 / NCI-2019-05943

Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer

AI 简述这是一项II期试验，优化吉西他滨和白蛋白紫杉醇输注方案用于转移性胰腺癌。

?

适用疾病: Metastatic Pancreatic Adenocarcinoma；Stage IV Pancreatic Cancer AJCC v8；Stage IV Pancreatic Cancer
干预: Gemcitabine，Nab-paclitaxel
地点: United States
申办方: Anne Noonan

正在招募 Phase 1, Phase 2 药物其他手术/操作

ClinicalTrials.gov / NCI NCT04172532 / NCI-2019-07645

Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer

AI 简述这是一项I/II期试验，在美国研究Peposertib联合放疗用于局部晚期胰腺癌。

?

适用疾病: Locally Advanced Pancreatic Adenocarcinoma；Stage III Pancreatic Cancer AJCC v8；Stage III Pancreatic Cancer
干预: Biopsy Procedure，Biospecimen Collection，Computed Tomography，Hypofractionated Radiation Therapy
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT04421820 / NCI-2021-14002

BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours

AI 简述这是一项I/II期试验，研究BOLD-100联合FOLFOX用于晚期实体瘤，在美国、加拿大、德国、爱尔兰等地开展。

?

适用疾病: Colorectal Cancer；Pancreatic Cancer；Gastric Cancers
干预: BOLD-100 +/- FOLFOX Chemotherapy (Arm VII)，BOLD-100 in combination with FOLFOX Chemotherapy (Arms I-VI)
地点: United States，Canada，Germany，Ireland 等 3 个
申办方: Bold Therapeutics, Inc.

正在招募 Phase 2 药物

ClinicalTrials.gov NCT04452461

Pancreatic Adenocarcinoma Neoadjuvant Chemotherapy Before Surgery

AI 简述这是一项II期试验，研究mFOLFIRINOX或吉西他滨/白蛋白紫杉醇用于胰腺癌术前化疗，在加拿大开展。

?

适用疾病: Pancreatic Adenocarcinoma
干预: mFOLFIRINOX，Gemcitabine / Nab-paclitaxel
地点: Canada
申办方: Hamilton Health Sciences Corporation

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT04503265 / NCI-2020-14258

A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies

AI 简述这是一项I/II期试验，研究AMXI-5001用于晚期实体瘤。在美国开展。

?

适用疾病: Advanced Malignant Neoplasm；Breast Cancer；Ovarian Cancer
干预: AMXI-5001:Dose Escalation Phase I，AMXI-5001:Dose Expansion Phase II
地点: United States
申办方: AtlasMedx, Incorporated

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT04543071 / NCI-2020-06604

Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma

AI 简述这是一项2期试验，在美国研究Motixafortide、Cemiplimab联合化疗用于胰腺腺癌。

?

适用疾病: Pancreatic Cancer；Adenocarcinoma of the Pancreas；Adenocarcinoma
干预: Motixafortide，Cemiplimab，Gemcitabine，Nab paclitaxel
地点: United States
申办方: Gulam Manji

正在招募 Phase 2 药物手术/操作

ClinicalTrials.gov / NCI NCT04550494 / NCI-2020-06906

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

AI 简述这是一项II期试验，研究Talazoparib用于携带DNA修复变异的晚期癌症患者。

?

适用疾病: Anatomic Stage III Breast Cancer AJCC v8；Anatomic Stage IV Breast Cancer AJCC v8；Castration-Resistant Prostate Carcinoma
干预: Biopsy Procedure，Biospecimen Collection，Computed Tomography，Magnetic Resonance Imaging
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 2 联合产品放疗

ClinicalTrials.gov NCT04570943

Sequential Treatment With GEMBRAX and Then FOLFIRINOX Followed by Stereotactic MRI-guided Radiotherapy in Patients With Locally Advanced Pancreatic Cancer

AI 简述这是一项II期试验，研究GEMBRAX序贯FOLFIRINOX后行MRI引导立体定向放疗用于局部晚期胰腺癌，在法国开展。

?

适用疾病: Locally Advanced Pancreatic Adenocarcinoma
干预: Gabrinox，MRI-GUIDED STEREOTACTIC RADIOTHERAPY
地点: France
申办方: Institut du Cancer de Montpellier - Val d'Aurelle

正在招募 Phase 1, Phase 2 联合产品

ClinicalTrials.gov / NCI NCT04605913 / NCI-2022-01522

Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w/ Metastatic PAC

AI 简述这是一项1/2期试验，研究改良GCN+TTF方案用于转移性胰腺癌，在美国开展。

?

适用疾病: Pancreas Cancer；Metastatic Pancreatic Cancer；Pancreatic Adenocarcinoma
干预: Modified GCN+TTF treatment
地点: United States
申办方: Mayo Clinic

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT04657068 / NCI-2021-04129

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

AI 简述这是一项I/II期试验，研究ART0380联合吉西他滨或伊立替康用于晚期或转移性实体瘤。

?

适用疾病: Advanced Cancer；Metastatic Cancer；Ovarian Cancer
干预: ART0380，Gemcitabine，Irinotecan
地点: United States，France，Spain，United Kingdom
申办方: Artios Pharma Ltd

正在招募 Phase 2 药物

ClinicalTrials.gov NCT04683315

PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples

AI 简述这是一项II期试验，研究mFOLFIRINOX或吉西他滨/白蛋白紫杉醇用于胰腺癌的适应性新辅助化疗。

?

适用疾病: Pancreatic Cancer
干预: mFOLFIRINOX Treatment Regimen，Gemcitabine/Nab-paclitaxel Treatment Regimen
地点: United States
申办方: Medical College of Wisconsin

正在招募 Phase 1, Phase 2 药物放疗

ClinicalTrials.gov / NCI NCT04789486 / NCI-2021-06084

Nano-SMART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors and Pancreatic Cancer

AI 简述这是一项I/II期试验，在美国研究AGuIX纳米颗粒联合MR引导SBRT用于中央型肺癌和胰腺癌。

?

适用疾病: Non-small Cell Lung Cancer；Advanced Pancreatic Adenocarcinoma；Unresectable Pancreatic Cancer
干预: AGuIX，Radiotherapy
地点: United States
申办方: Dana-Farber Cancer Institute

正在招募 Phase 1, Phase 2 药物手术/操作

ClinicalTrials.gov / NCI NCT04851119 / NCI-2021-02852

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

AI 简述这是一项I/II期试验，研究Tegavivint用于复发或难治性实体瘤，包括淋巴瘤和硬纤维瘤。

?

适用疾病: Colorectal Carcinoma；Endometrial Carcinoma；Melanoma
干预: Biospecimen Collection，Dual X-ray Absorptiometry，Tegavivint，X-Ray Imaging
地点: United States
申办方: Children's Oncology Group

正在招募 Phase 2 药物手术/操作

ClinicalTrials.gov / NCI NCT04858009 / NCI-2021-02990

Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Pancreatic Cancer and Peritoneal Metastasis

AI 简述这是一项II期试验，研究腹腔热灌注化疗联合Cisplatin和Nab-paclitaxel用于胰腺癌腹膜转移，在美国开展。

?

适用疾病: Metastatic Pancreatic Carcinoma；Stage IV Pancreatic Cancer AJCC v8；Metastatic Malignant Neoplasm in the Peritoneum
干预: Cisplatin，Hyperthermic Intraperitoneal Chemotherapy，Nab-paclitaxel，Computed Tomography
地点: United States
申办方: Mayo Clinic

正在招募 Phase 2 药物手术/操作

ClinicalTrials.gov / NCI NCT04858334 / NCI-2020-05659

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

AI 简述这是一项II期试验，比较Olaparib与安慰剂用于携带BRCA1/2或PALB2突变的可切除胰腺癌，在美国、以色列、波多黎各开展。

?

适用疾病: Pancreatic Acinar Cell Carcinoma；Pancreatic Adenosquamous Carcinoma；Pancreatic Squamous Cell Carcinoma
干预: Biospecimen Collection，Computed Tomography，Magnetic Resonance Imaging，Olaparib
地点: United States，Israel，Puerto Rico
申办方: National Cancer Institute (NCI)

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT04895709

A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究BMS-986340单药或联合治疗用于晚期实体瘤，包括宫颈癌、肺癌等。

?

适用疾病: Cervical Cancer；Gastric/Gastroesophageal Junction Adenocarcinoma；Microsatellite Stable Colorectal Cancer
干预: BMS-986340，BMS-936558-01，Docetaxel，Pumitamig
地点: United States，Australia，Canada，Germany 等 4 个
申办方: Bristol-Myers Squibb

正在招募 Phase 2 药物

ClinicalTrials.gov NCT04926467

Chemotherapy + Anakinra in Patients With Pancreatic Adenocarcinoma (PDAC)

AI 简述这是一项II期试验，研究化疗联合Anakinra用于胰腺腺癌，在美国开展。

?

适用疾病: Pancreatic Adenocarcinoma
干预: Anakinra
地点: United States
申办方: Baylor Research Institute

正在招募 Phase 2 器械药物

ClinicalTrials.gov / NCI NCT04990609 / NCI-2024-09908

EUS-RFA PANCARDINAL-1 Trial

AI 简述这是一项II期试验，研究超声内镜引导射频消融联合新辅助化疗用于胰腺导管腺癌。

?

适用疾病: Pancreatic Ductal Adenocarcinoma (PDAC)；Pancreatic Ductal Adenocarcinoma
干预: Endoscopic Ultrasound (EUS)-Guided Radiofrequency Ablation (RFA)，Neoadjuvant Chemotherapy (NAC)
地点: United States
申办方: The University of Texas Health Science Center, Houston

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT05000294 / NCI-2023-08761

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

AI 简述这是一项I/II期试验，研究阿特珠单抗联合Tivozanib用于免疫冷肿瘤类型，在美国开展。

?

适用疾病: Bile Duct Cancer；Gall Bladder Cancer；Breast Cancer
干预: Atezolizumab，Tivozanib
地点: United States
申办方: University of Florida

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05040360

Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors

AI 简述这是一项II期试验，研究手术后化疗用于高风险胰腺神经内分泌肿瘤。

?

适用疾病: Metastatic Malignant Neoplasm in the Liver；Pancreatic Neuroendocrine Tumor；Stage I Pancreatic Neuroendocrine Tumor AJCC v8
干预: Capecitabine，Temozolomide
地点: United States，Mexico，Uruguay
申办方: SWOG Cancer Research Network

正在招募 Phase 1, Phase 2 药物手术/操作

ClinicalTrials.gov / NCI NCT05053971 / NCI-2021-09727

Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors

AI 简述这是一项I/II期试验，研究Entinostat和ZEN003694用于晚期难治实体瘤。

?

适用疾病: Advanced Malignant Solid Neoplasm；Locally Advanced Pancreatic Carcinoma；Metastatic Pancreatic Carcinoma
干预: BET Bromodomain Inhibitor ZEN-3694，Computed Tomography，Core Biopsy，Entinostat
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 2 联合产品

ClinicalTrials.gov NCT05065801

Efficacy of Gembrax Followed by Folfirinox Versus Folfirinox Alone in First Metastatic Line Pancreatic Cancer Patients

AI 简述这是一项2期试验，比较Gembrax后接Folfirinox与单用Folfirinox用于转移性胰腺癌一线治疗，在法国开展。

?

适用疾病: Metastatic Pancreatic Cancer
干预: GEMBRAX/FOLFIRINOX Arm A，FOLFIRINOX Arm B
地点: France
申办方: Institut du Cancer de Montpellier - Val d'Aurelle

正在招募 Phase 2 药物手术/操作放疗

ClinicalTrials.gov NCT05083247

Preoperative mFOLFIRINOX (or Gem-Nab-P) +/- Isotoxic High-dose SBRT for Borderline Resectable Pancreatic Adenocarcinoma

AI 简述这是一项II期试验，研究术前mFOLFIRINOX或吉西他滨-白蛋白紫杉醇联合高剂量SBRT用于交界可切除胰腺癌。

?

适用疾病: Pancreatic Neoplasm；Pancreatic Adenocarcinoma；Borderline Resectable Pancreatic Adenocarcinoma
干预: mFOLFIRINOX or Gemcitabine nab-paclitaxel，Isotoxic High-Dose (iHD)-SBRT，Surgery
地点: Belgium
申办方: Erasme University Hospital

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05093231

Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer

AI 简述这是一项II期试验，研究Pembrolizumab联合Olaparib用于转移性胰腺癌。

?

适用疾病: Pancreatic Cancer
干预: Pembrolizumab，Olaparib
地点: Australia，United Kingdom
申办方: Cambridge University Hospitals NHS Foundation Trust

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT05132504 / NCI-2022-08323

Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer

AI 简述这是一项II期试验，研究新辅助Folfirinox联合帕博利珠单抗用于可切除胰腺癌，在美国开展。

?

适用疾病: Pancreatic Ductal Adenocarcinoma；Stage 0 Pancreatic Cancer；Stage I Pancreatic Cancer
干预: Pembrolizumab，Folfirinox
地点: United States
申办方: Baylor College of Medicine

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT05141149

First in Human Phase1/2a Clinical Trial of Anti-PAUF Monoclonal Antibody PBP1510 in Patients With Pancreatic Cancer

AI 简述这是一项I/IIa期试验，研究抗PAUF单克隆抗体PBP1510用于胰腺癌，在美国等多国开展。

?

适用疾病: Pancreatic Cancer
干预: PBP1510 (400mg/16mL)，Gemcitabine (1000 mg/m^2)
地点: United States，Australia，Singapore，Spain
申办方: Prestige Biopharma Limited

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT05257993

Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Advanced and Metastatic Pancreatic Cancer

AI 简述这是一项I/II期试验，研究JPI-547联合mFOLFIRINOX或吉西他滨-白蛋白紫杉醇用于局部晚期和转移性胰腺癌。

?

适用疾病: Pancreatic Ductal Adenocarcinoma
干预: JPI-547，modified FOLFIRINOX，Gemcitabine-nab-paclitaxel
地点: South Korea
申办方: Onconic Therapeutics Inc.

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT05379985 / NCI-2022-05170

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

AI 简述这是一项I/II期试验，研究RMC-6236用于携带特定RAS突变的晚期实体瘤。

?

适用疾病: Non-small Cell Lung Cancer (NSCLC)；Colorectal Cancer (CRC)；Pancreatic Ductal Adenocarcinoma (PDAC)
干预: RMC-6236
地点: United States
申办方: Revolution Medicines, Inc.

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT05431270 / NCI-2022-06838

Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

AI 简述这是一项I/II期试验，研究Mavrostobart单用或联合替雷利珠单抗或化疗用于晚期实体瘤。

?

适用疾病: Non Small Cell Lung Cancer；Pancreatic Ductal Adenocarcinoma；Metastatic Malignant Solid Tumor
干预: Mavrostobart (PT199)，Tislelizumab，Gemcitabine + nab-Paclitaxel，Docetaxel
地点: United States
申办方: Phanes Therapeutics

正在招募 Phase 2 生物制剂药物

ClinicalTrials.gov NCT05451043

Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)

AI 简述这是一项II期试验，研究Durvalumab和Tremelimumab联合普萘洛尔及化疗用于晚期肝胆肿瘤。

?

适用疾病: Pancreatic Cancer；Hepatocellular Cancer；Biliary Tract Cancer
干预: Durvalumab，Gemcitabine，Nab paclitaxel，Tremelimumab
地点: Canada
申办方: AHS Cancer Control Alberta

正在招募 Phase 2 药物手术/操作

ClinicalTrials.gov NCT05462496

Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer

AI 简述这是一项II期试验，研究肠道微生物调节联合Pembrolizumab用于可切除胰腺癌。

?

适用疾病: Pancreatic Cancer
干预: Biopsy，FOLFIRINOX，Ciprofloxacin，Metronidazole
地点: United States
申办方: Icahn School of Medicine at Mount Sinai

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05472259

A Study Evaluating the Efficacy of 5-FU + NALIRI and 5-FU + NALIRINOX for PDAC (NALPAC)

AI 简述这是一项II期试验，比较5-FU+NALIRI和5-FU+NALIRINOX用于转移性胰腺导管腺癌。

?

适用疾病: Metastatic Pancreatic Ductal Adenocarcinoma
干预: Nanoliposomal irinotecan，5 FU，Leucovorin，Oxaliplatin
地点: Belgium
申办方: Belgian Group of Digestive Oncology

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT05482893 / NCI-2022-10638

Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)

AI 简述这是一项1/2期试验，研究Spevatamig单药或联合化疗用于晚期胃腺癌、胰腺癌等，在美国开展。

?

适用疾病: Gastric or Gastroesophageal Junction Adenocarcinoma；Pancreatic Ductal Adenocarcinoma；Biliary Tract Cancer (BTC)
干预: Spevatamig (PT886)，Paclitaxel，Gemcitabine，Abraxane
地点: United States
申办方: Phanes Therapeutics

正在招募 Phase 2 器械药物

ClinicalTrials.gov / NCI NCT05624918 / NCI-2024-06195

A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma

AI 简述这是一项II期试验，研究NovoTTF-200T(P)联合吉西他滨和白蛋白结合型紫杉醇用于可切除胰腺癌，在美国开展。

?

适用疾病: Pancreatic Adenocarcinoma；Resectable Pancreatic Cancer；Resectable Pancreatic Adenocarcinoma
干预: Nab paclitaxel，Gemcitabine，NovoTTF-200T(P)
地点: United States
申办方: Ashish Manne

正在招募 Phase 1, Phase 2 药物手术/操作

ClinicalTrials.gov / NCI NCT05688215 / NCI-2022-10208

Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma

AI 简述这是一项I/II期试验，研究Zimberelimab和Quemliclustat联合化疗用于交界可切除和局部晚期胰腺腺癌，在美国开展。

?

适用疾病: Borderline Resectable Pancreatic Adenocarcinoma；Locally Advanced Pancreatic Ductal Adenocarcinoma；Borderline Resectable Pancreatic Ductal Adenocarcinoma
干预: Biospecimen Collection，Computed Tomography，Core Biopsy，Fluorouracil
地点: United States
申办方: Jonsson Comprehensive Cancer Center

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT05706129

A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors

AI 简述这是一项I/II期试验，研究[68Ga]Ga-DPI-4452和[177Lu]Lu-DPI-4452用于多种晚期实体瘤。在澳大利亚、法国等地开展。

?

适用疾病: Clear Cell Renal Cell Cancer (ccRCC)；Pancreatic Ductal Adenocarcinoma (PDAC)；Colorectal Cancer (CRC)
干预: [68Ga]Ga-DPI-4452，[177Lu]Lu-DPI-4452
地点: Australia，France
申办方: ITM Oncologics GmbH

正在招募 Phase 2 药物手术/操作

ClinicalTrials.gov NCT05733000

CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors

AI 简述这是一项2期试验，研究Devimistat联合羟氯喹和氟尿嘧啶或吉西他滨用于晚期难治性实体瘤。

?

适用疾病: Advanced Biliary Tract Carcinoma；Advanced Colorectal Carcinoma；Advanced Gastroesophageal Junction Adenocarcinoma
干预: Biospecimen Collection，Computed Tomography，Devimistat，Fluorouracil
地点: United States
申办方: Northwestern University

正在招募 Phase 2 器械药物

ClinicalTrials.gov / NCI NCT05776524 / NCI-2025-02281

Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields in Metastatic Pancreatic Cancer

AI 简述这是一项II期试验，研究调幅射频电磁场联合化疗用于转移性胰腺癌。

?

适用疾病: Pancreatic Cancer；Metastatic Adenocarcinoma；Stage IV Pancreatic Cancer
干预: Nab paclitaxel，Gemcitabine，TheraBionic
地点: United States
申办方: THERABIONIC INC.

正在招募 Phase 2 药物其他

ClinicalTrials.gov / NCI NCT05825066 / NCI-2023-06306

Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma

AI 简述这是一项II期试验，研究Nab paclitaxel和Gemcitabine用于交界可切除和局部晚期胰腺癌。

?

适用疾病: Pancreas Adenocarcinoma；Borderline Resectable Pancreatic Adenocarcinoma；Locally Advanced Pancreatic Adenocarcinoma
干预: Nab paclitaxel，Gemcitabine，Radiological Assessments，mFOLFIRINOX
地点: United States
申办方: Wake Forest University Health Sciences

正在招募 Phase 2 联合产品药物

ClinicalTrials.gov / NCI NCT05851924 / NCI-2023-04160

A Study of NALIRIFOX in Combination With Radiation Therapy in People With Pancreatic Ductal Adenocarcinoma (PDAC)

AI 简述这是一项2期试验，研究NALIRIFOX联合放疗用于胰腺导管腺癌。

?

适用疾病: Pancreatic Ductal Adenocarcinoma；Stage II Pancreatic Cancer；Stage III Pancreatic Cancer
干预: NALIRIFOX，AD-XRT and Capecitabine
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05929885

Metronomic Capecitabine, Oxaliplatin and UGT1A1 Genotype-directed Irinotecan in Metastatic Pancreatic Cancer Patients

AI 简述这是一项II期试验，研究低剂量OXIRI用于转移性胰腺癌，在新加坡开展。

?

适用疾病: Metastatic Pancreatic Cancer
干预: Low Dose OXIRI (LD-OXIRI)
地点: Singapore
申办方: National Cancer Centre, Singapore

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT05968326 / NCI-2023-08759

A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC

AI 简述这是一项II期试验，研究Autogene cevumeran联合Atezolizumab和mFOLFIRINOX用于切除的胰腺导管腺癌。

?

适用疾病: Adenocarcinoma, Pancreatic Ductal；Stage I Pancreatic Cancer；Stage II Pancreatic Cancer
干预: Autogene cevumeran，Atezolizumab，mFOLFIRINOX
地点: United States，Belgium，Canada，France 等 6 个
申办方: Genentech, Inc.

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT05985655 / NCI-2026-01491

Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究GTAEXS617用于多种晚期实体瘤。

?

适用疾病: Head and Neck Squamous Cell Carcinoma (HNSCC)；Pancreatic Adenocarcinoma；Non-small Cell Lung Cancer (NSCLC)
干预: GTAEXS617，SoC
地点: United States，Belgium，United Kingdom
申办方: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05988814

Trial Evaluating the Efficacy and the Safety of FOLFIRINOX3 Treatment in Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer in First Line of Chemotherapy

AI 简述这是一项II期试验，研究FOLFIRINOX方案用于不可切除局部晚期或转移性胰腺癌一线治疗，在法国开展。

?

适用疾病: Metastatic Pancreatic Cancer
干预: FOLFIRINOX treatment
地点: France
申办方: Centre Georges Francois Leclerc

正在招募 Phase 4 药物手术/操作

ClinicalTrials.gov NCT06016855

Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors

AI 简述这是一项IV期试验，研究肿瘤减灭术联合Lu177 dotatate用于胃肠胰神经内分泌肿瘤。

?

适用疾病: Digestive System Neuroendocrine Tumor G1；Digestive System Neuroendocrine Tumor G2；Metastatic Digestive System Neuroendocrine Neoplasm
干预: Tumor Debulking，Lutetium Lu 177 Dotatate，Computed Tomography，Magnetic Resonance Imaging
地点: United States
申办方: Vanderbilt-Ingram Cancer Center

正在招募 Phase 1, Phase 2 放疗

ClinicalTrials.gov NCT06024824

Dose-Painted Intensity Modulated Radiotherapy Pancreas (DP-IMRT Pancreas)

AI 简述这是一项I/II期试验，研究剂量调强放疗用于胰腺腺癌。在爱尔兰开展。

?

适用疾病: Pancreatic Adenocarcinoma
干预: Dose-Painted Intensity Modulated Radiotherapy
地点: Ireland
申办方: Cancer Trials Ireland

正在招募 Phase 2 药物放疗

ClinicalTrials.gov / NCI NCT06048484 / NCI-2024-00944

Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma

AI 简述这是一项II期试验，在美国开展，研究立体定向放疗联合Zimberelimab、Quemliclustat和Etrumadenant用于局部晚期胰腺癌。

?

适用疾病: Pancreatic Ductal Adenocarcinoma；Stage III Pancreatic Cancer；Locally Advanced Pancreatic Adenocarcinoma
干预: Stereotactic body radiotherapy (SBRT)，Zimberelimab，Quemliclustat，Etrumadenant
地点: United States
申办方: Gulam Manji

正在招募 Phase 1, Phase 2 生物制剂诊断检测

ClinicalTrials.gov / NCI NCT06051695 / NCI-2024-01620

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

AI 简述这是一项I/II期试验，在美国开展，研究间皮素靶向逻辑门控CAR-T细胞用于表达MSLN且失去HLA-A*02表达的实体瘤。

?

适用疾病: Solid Tumor, Adult；Colorectal Cancer；NSCLC
干预: A2B694，A2B543，xT CDx with HLA-LOH Assay
地点: United States
申办方: A2 Biotherapeutics Inc.

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06060405

Durvalumab and Oleclumab in Resectable PDAC

AI 简述这是一项2期试验，研究度伐利尤单抗联合Oleclumab用于可切除胰腺导管腺癌。

?

适用疾病: Pancreatic Ductal Adenocarcinoma
干预: Durvalumab，Oleclumab
地点: Canada
申办方: University Health Network, Toronto

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06078787

Olaparib in PALB2 Advanced Pancreatic Cancer

AI 简述这是一项II期试验，研究Olaparib用于PALB2突变的晚期胰腺癌。

?

适用疾病: Advanced Pancreatic Cancer；Metastatic Pancreatic Cancer
干预: Olaparib 150 MG
地点: Italy
申办方: Azienda Ospedaliero-Universitaria di Modena

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT06128551

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

AI 简述这是一项1/2期试验，研究Elironrasib和Daraxonrasib单药或联合用于KRAS G12C突变实体瘤。

?

适用疾病: Non-Small Cell Lung Cancer (NSCLC)；Colorectal Cancer；Pancreatic Ductal Adenocarcinoma
干预: Elironrasib，Daraxonrasib
地点: United States，France，Germany，Italy 等 3 个
申办方: Revolution Medicines, Inc.

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06145074

Examining Safety, Efficacy and Feasibility of Preoperative Propranolol in Patients With PDAC.

AI 简述这是一项II期试验，研究术前普萘洛尔用于胰腺导管腺癌。

?

适用疾病: Pancreatic Cancer；Surgery
干预: Propranolol，Placebo
地点: Denmark
申办方: Zealand University Hospital

正在招募 Phase 2 生物制剂药物手术/操作

ClinicalTrials.gov NCT06202066

Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas

AI 简述这是一项II期试验，在美国研究替莫唑胺和SurVaxM疫苗用于进展期转移性神经内分泌癌。

?

适用疾病: Digestive System Neuroendocrine Neoplasm；Lung Neuroendocrine Neoplasm；Malignant Solid Neoplasm
干预: Biospecimen Collection，Computed Tomography，Incomplete Freund''s Adjuvant，Magnetic Resonance Imaging
地点: United States
申办方: Roswell Park Cancer Institute

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT06244771

A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors

AI 简述这是一项I/II期试验，研究FMC-376用于KRAS G12C突变的晚期实体瘤。

?

适用疾病: Advanced Solid Tumors With KRAS G12C Mutations；Solid Tumor, Adult；Unresectable Solid Tumor
干预: FMC-376
地点: United States，Australia，South Korea
申办方: Frontier Medicines Corporation

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06333314

Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI

AI 简述这是一项II期试验，研究Dostarlimab用于dMMR/MSI的局部晚期或转移性癌症。

?

适用疾病: Pancreatic Adenocarcinoma；Ampulla of Vater Carcinoma；Adrenocortical Carcinoma
干预: Dostarlimab，Chemotherapy
地点: France
申办方: UNICANCER

正在招募 Phase 1, Phase 2 药物放疗

ClinicalTrials.gov NCT06384560

Neoadjuvant Triple Therapy for (Borderline) Resectable Pancreatic Cancer (PREOPANC-5)

AI 简述这是一项I/II期试验，研究Pembrolizumab、Folfirinox和SABR新辅助治疗用于（交界性）可切除胰腺癌，在荷兰开展。

?

适用疾病: Localized Pancreatic Adenocarcinoma；Borderline Resectable Pancreatic Adenocarcinoma；Resectable Pancreatic Adenocarcinoma
干预: Pembrolizumab，Folfirinox，SABR
地点: Netherlands
申办方: Amsterdam UMC, location VUmc

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06387342

Namodenoson Treatment of Advanced Pancreatic Cancer

AI 简述这是一项II期试验，研究Namodenoson用于晚期胰腺癌，在以色列开展。

?

适用疾病: Pancreatic Adenocarcinoma；Pancreatic Cancer
干预: Namodenoson 25mg
地点: Israel
申办方: Can-Fite BioPharma

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT06399757 / NCI-2024-04491

A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究APL-5125用于晚期实体瘤。在美国开展。

?

适用疾病: Colorectal Cancer；Cholangiocarcinoma；Appendiceal Adenocarcinoma
干预: APL-5125
地点: United States
申办方: Apollo Therapeutics Ltd

正在招募 Phase 2 药物手术/操作

ClinicalTrials.gov / NCI NCT06423326 / NCI-2024-02082

Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer

AI 简述这是一项II期试验，研究吉西他滨、顺铂和白蛋白紫杉醇用于可切除或交界性可切除胰腺癌的新辅助治疗。在美国开展。

?

适用疾病: Borderline Resectable Pancreatic Ductal Adenocarcinoma；Resectable Pancreatic Adenocarcinoma；Stage I Pancreatic Cancer AJCC v8
干预: Biopsy，Biospecimen Collection，Cisplatin，Computed Tomography
地点: United States
申办方: Emory University

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT06445062 / NCI-2024-05164

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

AI 简述这是一项I/II期试验，研究RMC-6236联合化疗用于胃肠道实体瘤。

?

适用疾病: Colorectal Cancer；CRC；Pancreatic Ductal Adenocarcinoma
干预: RMC-6236，mFOLFOX6 regimen，bevacizumab，mFOLFIRINOX regimen
地点: United States
申办方: Revolution Medicines, Inc.

正在招募 Phase 2 放疗

ClinicalTrials.gov NCT06453486

A Study of High Dose Radiation Therapy for Locally Advanced Pancreatic Cancer That Responded to Initial Chemotherapy Treatment

AI 简述这是一项II期试验，研究高剂量放疗用于局部晚期胰腺癌。

?

适用疾病: Locally Advanced Pancreatic Adenocarcinoma
干预: High dose radiation therapy
地点: Canada
申办方: University Health Network, Toronto

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT06479239 / NCI-2024-06646

Study of EGFRBi Armed Fresh PBMC in Metastatic or Unresectable Pancreatic Cancer

AI 简述这是一项I/II期试验，研究EGFR FPBMC用于转移性或不可切除胰腺癌，在美国开展。

?

适用疾病: Pancreas Cancer；Pancreatic Cancer；Stage II Pancreatic Cancer
干预: EGFR FPBMC
地点: United States
申办方: University of Virginia

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT06483555 / NCI-2025-00301

Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel

AI 简述这是一项I/II期试验，研究吉西他滨、厄洛替尼和白蛋白紫杉醇用于基底样胰腺癌，在美国开展。

?

适用疾病: Pancreatic Adenocarcinoma；Metastatic Pancreatic Cancer；Basal Cell Neoplasm
干预: Gemcitabine，Nab paclitaxel，Erlotinib，NALIRIFOX
地点: United States
申办方: UNC Lineberger Comprehensive Cancer Center

正在招募 Phase 2 器械药物

ClinicalTrials.gov / NCI NCT06576115 / NCI-2024-07331

Gemcitabine, Nab-paclitaxel Plus the TheraBionic P1 (an Amplitude-Modulated Radiofrequency Electromagnetic Fields) Device to Treat Metastatic Pancreatic Cancer

AI 简述这是一项II期试验，研究吉西他滨、白蛋白紫杉醇联合TheraBionic P1设备治疗转移性胰腺癌。

?

适用疾病: Metastatic Pancreatic Adenocarcinoma；Stage IV Pancreatic Cancer
干预: Nab paclitaxel，Gemcitabine，TheraBionic P1
地点: United States
申办方: Barbara Ann Karmanos Cancer Institute

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT06598007 / NCI-2024-07992

A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究CT3001单用或联合FOLFOX用于多种晚期实体瘤，在美国开展。

?

适用疾病: Solid Tumor, Adult；Colorectal Cancer；Pancreatic Ductal Adenocarcinoma
干预: CT3001，FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)
地点: United States
申办方: Crossignal Therapeutics, Inc.

正在招募 Phase 2 手术/操作

ClinicalTrials.gov NCT06690528

Conversion Surgery Vs. Palliative Care in Pancreatic Cancer Oligometastatic to the Liver

AI 简述这是一项II期试验，比较转化手术与姑息治疗用于胰腺癌肝寡转移，在意大利开展。

?

适用疾病: Pancreatic Cancer Metastatic
干预: Surgical resection of both the primary tumor and liver metastases
地点: Italy
申办方: Azienda Ospedaliera di Padova

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT06710756

Lead-212 PSV359 Therapy for Patients With Solid Tumors

AI 简述这是一项I/II期试验，研究[212Pb]Pb-PSV359治疗用于胰腺癌、胃癌、食管癌等实体瘤。在美国开展。

?

适用疾病: Pancreatic Ductal Adenocarcinoma；Gastric Cancer；Esophageal Cancer
干预: [203Pb]Pb-PSV359，[212Pb]Pb-PSV359
地点: United States
申办方: Perspective Therapeutics

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06747845 / NCI-2025-03632

Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based Chemotherapy

AI 简述这是一项II期试验，研究尼拉帕利联合伊匹木单抗维持治疗用于转移性胰腺癌，在美国开展。

?

适用疾病: Pancreatic Adenocarcinoma Metastatic；Stage IV Pancreatic Cancer；Metastatic Pancreatic Adenocarcinoma
干预: Niraparib，FOLFIRI，Ipilimumab
地点: United States
申办方: Abramson Cancer Center at Penn Medicine

正在招募 Phase 2 药物手术/操作

ClinicalTrials.gov NCT06756074

Reinforced Pancreaticojejunostomy With or Without glubran2

AI 简述这是一项II期试验，比较加强胰肠吻合术与标准术用于胰腺癌患者。

?

适用疾病: Pancreatic Fistula；Pancreas Cancer；Periampullary Carcinoma
干预: Reinforced pancreaticojejunostomy with tissue adhesive glue modified cyanoacrylate (glubran 2)，Pancreaticojejunostomy without tissue adhesive glue modified cyanoacrylate (glubran 2)
地点: Egypt
申办方: Minia University

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT06782555 / NCI-2025-00867

A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab

AI 简述这是一项I/II期试验，研究Evofosfamide联合Zalifrelimab和Balstilimab用于转移性前列腺癌、头颈鳞癌及胰腺癌。

?

适用疾病: Metastatic Prostate Cancer；Metastatic Head and Neck Squamous Cell Carcinoma；Metastatic Pancreatic Cancer
干预: Evofosfamide，Zalifrelimab，Balstilimab
地点: United States
申办方: ImmunoGenesis

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT06782932 / NCI-2025-03838

Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer

AI 简述这是一项I/II期试验，比较GVAX与mKRASvax联合PD-1和CD137抗体用于可切除胰腺癌的术前/术后治疗。

?

适用疾病: Pancreatic Cancer；Stage I Pancreatic Cancer；Stage II Pancreatic Cancer
干预: AGEN2373，Balstilimab，Cyclophosphamide，GVAX
地点: United States
申办方: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06790602 / NCI-2026-01066

Cemiplimab Plus Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma

AI 简述这是一项II期试验，研究Cemiplimab联合吉西他滨用于转移性胰腺癌。在美国开展。

?

适用疾病: Pancreatic Ductal Adenocarcinoma (mPDAC)；Stage IV Pancreatic Cancer；Metastatic Pancreatic Adenocarcinoma
干预: Cemiplimab Plus Gemcitabine
地点: United States
申办方: University of California, San Diego

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06813079

Using Tumor Models to Determine Treatments

AI 简述这是一项II期试验，在加拿大开展，使用肿瘤模型指导治疗，涉及Cobimetinib等药物用于晚期实体瘤。

?

适用疾病: Pancreatic Ductal Carcinoma；Advanced Cancer；Epithelial Tumor
干预: Cobimetinib，Ponatinib，Brigatinib，Colchicine
地点: Canada
申办方: University Health Network, Toronto

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06816914

Perioperative NALIRIFOX (liposomal Irinotecan in Combination with Fluorouracil, Leucovorin, and Oxaliplatin) in Resectable Pancreatic Adenocarcinoma: Randomized Phase II Trial

AI 简述这是一项II期试验，研究NALIRIFOX围手术期用于可切除胰腺腺癌，在台湾开展。

?

适用疾病: Resectable Pancreatic Adenocarcinoma
干预: NALIRIFOX
地点: Taiwan
申办方: Taichung Veterans General Hospital

正在招募 Phase 2 药物手术/操作

ClinicalTrials.gov / NCI NCT06821997 / NCI-2025-00732

NALIRIFOX Before Surgery for the Treatment of Borderline Resectable Pancreatic Ductal Adenocarcinoma, Nectar Trial

AI 简述这是一项II期试验，在美国开展，研究NALIRIFOX方案用于临界可切除胰腺导管腺癌的术前治疗。

?

适用疾病: Borderline Resectable Pancreatic Ductal Adenocarcinoma
干预: Biospecimen Collection，Computed Tomography，Fluorouracil，Irinotecan Sucrosofate
地点: United States
申办方: Roswell Park Cancer Institute

正在招募 Phase 2 器械药物

ClinicalTrials.gov NCT06831136

Endoscopic Ultrasound Radiofrequency Ablation and Immunotherapy Pembrolizumab for Locally Advanced Unresectable and Metastatic Pancreatic Duct Adenocarcinoma

AI 简述这是一项II期试验，研究内镜超声射频消融联合帕博利珠单抗用于局部晚期不可切除和转移性胰腺导管腺癌患者。

?

适用疾病: Pancreatic Ductal Adenocarcinoma
干预: Neoadjuvant Chemotherapy (NAC)，Immunotherapy (pembrolizumab)，Endoscopic ultrasound (EUS)-guided radiofrequency ablation (RFA)
地点: United States
申办方: The University of Texas Health Science Center, Houston

正在招募 Phase 2 药物放疗

ClinicalTrials.gov / NCI NCT06843551 / NCI-2025-04589

The Miami "EMPIRE" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation

AI 简述这是一项II期试验，研究SBRT联合Botensilimab和Balstilimab用于转移性胰腺癌。

?

适用疾病: Metastatic Pancreatic Ductal Adenocarcinoma；Metastatic Pancreatic Cancer；Stage IV Pancreatic Cancer
干预: Stereotactic Body Radiation Therapy，Botensilimab，Balstilimab
地点: United States
申办方: Benjamin Spieler

正在招募 Phase 2 联合产品药物

ClinicalTrials.gov NCT06850623

Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer

AI 简述这是一项II期试验，研究Acoustic Cluster Therapy联合化疗用于局部晚期胰腺癌。在美国和英国等地开展。

?

适用疾病: Locally Advanced Pancreatic Adenocarcinoma
干预: Acoustic Cluster Therapy，Modified FOLFIRINOX
地点: United States，United Kingdom
申办方: EXACT Therapeutics AS

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT06861452

Phase I/IIa Study: RR001 Administered Following Chemotherapy Cycles for Patients With Locally Advanced Pancreatic Carcinoma

AI 简述这是一项I/IIa期试验，研究RR001用于局部晚期胰腺癌。

?

适用疾病: Locally Advanced Pancreatic Adenocarcinoma
干预: RR001
地点: Italy
申办方: EIR Biotherapies s.r.l.

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT06904378 / NCI-2026-01126

ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma

AI 简述这是一项I/II期试验，研究ONT01联合吉西他滨/白蛋白紫杉醇用于转移性胰腺导管腺癌的二线治疗，在美国开展。

?

适用疾病: Metastatic Pancreatic Ductal Adenocarcinoma；Stage II Pancreatic Cancer；Stage III Pancreatic Cancer
干预: ONT01，Gemcitabine，Nab paclitaxel
地点: United States
申办方: Washington University School of Medicine

正在招募 Phase 2 药物手术/操作

ClinicalTrials.gov / NCI NCT06906562 / NCI-2025-03043

A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations

AI 简述这是一项II期试验，研究Pemigatinib用于FGFR基因改变的晚期胰腺癌。

?

适用疾病: Advanced Pancreatic Carcinoma；Metastatic Pancreatic Carcinoma；Stage II Pancreatic Cancer AJCC v8
干预: Pemigatinib，Computed Tomography (CT)，Magnetic Resonance Imaging，Optical Coherence Tomography
地点: United States
申办方: Sameek Roychowdhury

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT06922591 / NCI-2025-04690

Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

AI 简述这是一项I/II期试验，研究TNG462联合RMC-9805等用于PDAC和NSCLC，在美国开展。

?

适用疾病: PDAC；PDAC - Pancreatic Ductal Adenocarcinoma；NSCLC
干预: TNG462，RMC-9805，RMC-6236，mFOLFIRINOX
地点: United States
申办方: Tango Therapeutics, Inc.

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06941857 / NCI-2025-05386

NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer

AI 简述这是一项2期试验，研究NC410和FOLFIRINOX联合纳武利尤单抗用于转移性胰腺癌。

?

适用疾病: Pancreatic Cancer；Stage IV Pancreatic Cancer；Metastatic Pancreatic Ductal Adenocarcinoma
干预: Oxaliplatin，Irinotecan，Folinic Acid，5-Fluorouracil (5-FU)
地点: United States
申办方: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT06943521 / NCI-2025-04636

A Study of MT-4561 in Patients With Various Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究MT-4561用于多种晚期实体瘤，在美国和日本开展。

?

适用疾病: Head and Neck Squamous Cell Carcinoma (HNSCC)；Non-small Cell Lung Cancer (NSCLC)；Esophageal Cancer
干预: MT-4561
地点: United States，Japan
申办方: Tanabe Pharma America, Inc.

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT07020221 / NCI-2025-04955

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

AI 简述这是一项I/II期试验，研究VS-7375用于KRAS G12D突变实体瘤，在美国、澳大利亚等地开展。

?

适用疾病: Pancreatic Ductal Adenocarcinoma；Non Small Cell Lung Cancer；Colorectal Cancer
干预: VS-7375，Cetuximab，Carboplatin + Pemetrexed + Pembrolizumab，Gemcitabine
地点: United States，Australia
申办方: Verastem, Inc.

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT07030257 / NCI-2025-08127

Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors

AI 简述这是一项1/2期试验，研究CP-383用于晚期或转移性实体瘤，包括结直肠癌、小细胞肺癌等。

?

适用疾病: Solid Tumor Malignancies；Colorectal Carcinoma；Small Cell Lung Cancer ( SCLC )
干预: CP-383
地点: United States
申办方: Tasca Therapeutics

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT07049055 / NCI-2025-08615

A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer

AI 简述这是一项I/II期试验，研究EDV纳米细胞疗法联合吉西他滨和纳武紫杉醇用于转移性胰腺癌。

?

适用疾病: Pancreatic Cancer, Metastatic；PDAC - Pancreatic Ductal Adenocarcinoma；Stage IV Pancreatic Cancer
干预: E-EDV-D682，EDV-GC，Gemcitabine，Nab paclitaxel.
地点: United States
申办方: Engeneic Pty Limited

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT07076212 / NCI-2025-09121

Evaluating NALIRIFOX vs Modified Gemcitabine, Nab-Paclitaxel and Cisplatin in Patients With Locally Advanced and Metastatic Pancreatic Adenocarcinoma

AI 简述这是一项II期试验，比较NALIRIFOX与改良吉西他滨、白蛋白紫杉醇、顺铂用于局部晚期或转移性胰腺癌。

?

适用疾病: Metastatic Pancreatic Adenocarcinoma；Locally Advanced Pancreatic Adenocarcinoma；Stage II Pancreatic Cancer
干预: Liposomal Irinotecan，Oxaliplatin，5-Fluorouracil，Leucovorin
地点: United States
申办方: Medical University of South Carolina

正在招募 Phase 2 诊断检测药物

ClinicalTrials.gov / NCI NCT07096362 / NCI-2025-06277

Utility of ctDNA in Early Switch of First-line mFOLFIRINOX in Metastatic Pancreatic Ductal Adenocarcinoma

AI 简述这是一项2期试验，研究ctDNA引导早期转换一线mFOLFIRINOX用于转移性胰腺导管腺癌，在美国开展。

?

适用疾病: Metastatic Pancreatic Ductal Adenocarcinoma；Pancreatic Ductal Adenocarcinoma；Stage IV Pancreatic Cancer
干预: 5-Fluorouracil，Oxaliplatin，Leucovorin，Irinotecan
地点: United States
申办方: University of Miami

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT07114861

The KN510713 Study in Combination With mFOLFIRINOX

AI 简述这是一项I/II期试验，研究KN510联合KN713和mFOLFIRINOX用于局部晚期或转移性胰腺导管腺癌。在韩国开展。

?

适用疾病: Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
干预: Study drug: KN510 120mg/day + KN713 90mg/day, Combination Chemotherapy: mFOLFIRINOX，Study drug: KN510 120mg/day + KN713 120mg/day, Combination Chemotherapy: mFOLFIRINOX
地点: South Korea
申办方: New Cancer Cure-Bio Co.,Ltd.

正在招募 Phase 2 药物放疗

ClinicalTrials.gov / NCI NCT07126158 / NCI-2026-02060

Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma

AI 简述这是一项II期试验，研究立体定向放疗联合Defactinib和Avutometinib用于晚期胰腺癌，在美国开展。

?

适用疾病: Pancreatic Adenocarcinoma；Cancer of the Pancreas；Pancreas Cancer
干预: Stereotactic body radiotherapy，Defactinib，Avutometinib
地点: United States
申办方: Washington University School of Medicine

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT07148128

Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.

AI 简述这是一项1/2a期试验，研究WEF-001用于晚期KRAS突变实体瘤。

?

适用疾病: Advanced or Metastatic KRAS-mutant Tumor in Pancreatic Adenocarcinoma；Advanced or Metastatic KRAS-mutant Tumor in Colorectal Cancer；Advanced or Metastatic KRAS-mutant Tumor in Non Small Cell Lung Cancer
干预: WEF-001
地点: United States，Canada，United Kingdom
申办方: Auricula Biosciences Inc.

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT07157033 / NCI-2026-03302

A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.

AI 简述这是一项I/II期试验，研究XER-001联合立体定向放疗用于局部晚期胰腺癌。

?

适用疾病: Locally Advanced Pancreatic Adenocarcinoma；Locally Advanced Pancreas Cancer；Locally Advanced Pancreatic Ductal Adenocarcinoma
干预: XER-001
地点: United States
申办方: Xerient Pharma

正在招募 Phase 2 药物

ClinicalTrials.gov NCT07163273

Monthly Alternating NALIRIFOX and GnP in the First-Line Setting for Metastatic Pancreatic Ductal Adenocarcinoma

AI 简述这是一项2期试验，比较NALIRIFOX与GnP交替方案用于转移性胰腺癌一线治疗，在美国开展。

?

适用疾病: Pancreatic Ductal Adenocarcinoma
干预: NALIRIFOX，Gemcitabine plus nab-Paclitaxel (GnP)
地点: United States
申办方: Northwell Health

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT07172802

A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors

AI 简述这是一项I/II期试验，研究GI-108单药用于晚期或转移性实体瘤，包括非小细胞肺癌、头颈癌、胰腺癌，在韩国开展。

?

适用疾病: Advanced Solid Tumor；Metastatic Solid Tumor；Non-small Cell Lung Cancer (NSCLC)
干预: GI-108
地点: South Korea
申办方: GI Innovation, Inc.

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT07199764 / NCI-2025-09194

Maintenance Combinatorial Myeloid Immunotherapy for Unresectable Pancreatic Cancer

AI 简述这是一项II期试验，研究Odetiglucan联合Mitazalimab维持治疗用于不可切除胰腺癌。

?

适用疾病: Pancreatic Ductal Adenocarcinoma；Stage III Pancreatic Cancer；Stage IV Pancreatic Cancer
干预: Odetiglucan，Mitazalimab
地点: United States
申办方: University of Pennsylvania

正在招募 Phase 1, Phase 2 药物手术/操作

ClinicalTrials.gov / NCI NCT07214298 / NCI-2025-06680

Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma

AI 简述这是一项1/2期试验，研究Pegcetacoplan联合mFOLFIRINOX用于转移性胰腺导管腺癌。

?

适用疾病: Metastatic Pancreatic Ductal Adenocarcinoma；Stage IV Pancreatic Cancer AJCC v8；Stage IV Pancreatic Cancer
干预: Biopsy Procedure，Biospecimen Collection，Computed Tomography，Fluorouracil
地点: United States
申办方: Roswell Park Cancer Institute

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT07223047

A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies

AI 简述这是一项I/II期试验，研究BMS-986523单用或联合其他抗癌药物治疗晚期实体瘤。

?

适用疾病: Advanced Solid Malignancies；Non-small Cell Lung Cancer (NSCLC)；Colorectal Cancer (CRC)
干预: BMS-986523，Gemcitabine，Nab-Paclitaxel，Cetuximab
地点: United States，Canada，Spain
申办方: Bristol-Myers Squibb

正在招募 Phase 2 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT07226856 / NCI-2025-08032

BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma

AI 简述这是一项II期试验，研究BMS-986340联合Nivolumab、吉西他滨和紫杉醇用于转移性和复发性胰腺癌，在美国开展。

?

适用疾病: Metastatic Pancreatic Adenocarcinoma；Recurrent Pancreatic Adenocarcinoma；Stage IV Pancreatic Cancer AJCC v8
干预: Biopsy Procedure，Biospecimen Collection，Computed Tomography，Gemcitabine
地点: United States
申办方: Mayo Clinic

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT07259317 / NCI-2026-03245

Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma

AI 简述这是一项II期试验，研究Relacorilant联合白蛋白紫杉醇和吉西他滨用于转移性胰腺腺癌，在美国开展。

?

适用疾病: Adenocarcinoma；Carcinoma, Pancreatic Ductal；Stage IV Pancreatic Cancer
干预: Relacorilant，Nab-paclitaxel，Gemcitabine
地点: United States
申办方: Corcept Therapeutics

正在招募 Phase 2 放疗

ClinicalTrials.gov NCT07269626

PULSAR in Systemic Therapy for Pancreatic Cancer

AI 简述这是一项II期试验，研究个性化超分割适应性放疗用于局部晚期或交界可切除胰腺癌。

?

适用疾病: Locally Advanced Pancreatic Ductal Adenocarcinoma；Borderline Resectable Pancreatic Ductal Adenocarcinoma；Oligometastatic Pancreatic Ductal Adenocarcinoma
干预: Personalized Ultrafractionated Adaptive Radiotherapy
地点: South Korea
申办方: Samsung Medical Center

正在招募 Phase 1, Phase 2 联合产品

ClinicalTrials.gov NCT07284277

TTFields and Chemotherapy in Metastatic Pancreatic Adenocarcinoma (mPDAC)

AI 简述这是一项I/II期试验，研究TTFields联合化疗用于转移性胰腺腺癌。在西班牙开展。

?

适用疾病: Pancreatic Adenocarcinoma Metastatic；Pancreatic Ductal Adenocarcinoma
干预: TTFields concomitant with modFOLFIRINOX
地点: Spain
申办方: Clinica Universidad de Navarra, Universidad de Navarra

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT07450859 / NCI-2026-04101

A Study of Nuzefatide Pevedotin (BT5528) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

AI 简述这是一项2期试验，研究Nuzefatide Pevedotin (BT5528)用于转移性胰腺导管腺癌，在美国开展。

?

适用疾病: Pancreatic Ductal Adenocarcinoma (PDAC)；Stage IV Pancreatic Cancer；Metastatic Pancreatic Ductal Adenocarcinoma
干预: nuzefatide pevedotin (BT5528)
地点: United States
申办方: BicycleTx Limited

正在招募 Phase 2 药物

ClinicalTrials.gov NCT07483983

Study Investigating ASP3082 in Patients With Metastatic/Locally Advanced Non-small-cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC), With Biomarker Analysis to Characterize Response/Resistance

AI 简述这是一项II期试验，研究ASP3082用于转移性/局部晚期非小细胞肺癌和胰腺导管腺癌。

?

适用疾病: Metastatic/Locally Advanced Non-Small-Cell Lung Cancer；Metastatic/Locally Pancreatic Ductal Adenocarcinoma
干预: ASP3082
地点: France
申办方: Gustave Roussy, Cancer Campus, Grand Paris

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT07488676 / NCI-2026-04341

A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

AI 简述这是一项I/II期试验，研究ASP546C用于胃食管癌、胰腺癌或其他实体瘤，在美国和日本开展。

?

适用疾病: Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma；Pancreatic Adenocarcinoma；Metastatic Malignant Solid Tumor
干预: ASP546C
地点: United States，Japan
申办方: Astellas Pharma Global Development, Inc.

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT07529808

Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma

AI 简述这是一项I/II期试验，研究BHB810用于晚期胃癌和胃食管结合部腺癌。

?

适用疾病: Gastric Cancer；Gastric Adenocarcinoma；Gastric (Stomach) Cancer
干预: BHB810
地点: United States
申办方: BigHat Biosciences, Inc.

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT07629960

A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations

AI 简述这是一项I/II期试验，研究BLU-924用于KRAS突变晚期实体瘤，在美国开展。

?

适用疾病: Advanced Solid Tumor；Non-Small Cell Lung Cancer；Colorectal Neoplasms
干预: BLU-924
地点: United States
申办方: Blueprint Medicines Corporation

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT07644559 / NCI-2026-04622

A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer

AI 简述这是一项II期试验，研究VS-7375用于KRAS G12D突变胰腺癌，在美国和澳大利亚开展。

?

适用疾病: Pancreatic Ductal Adenocarcinoma (PDAC)；G12D Mutated KRAS；Stage IV Pancreatic Cancer
干预: VS-7375，cetuximab
地点: United States，Australia
申办方: Verastem, Inc.

即将招募 Phase 3 药物

ClinicalTrials.gov NCT05314998

Adjuvant Trial in Patients With Resected PDAC Randomized to Allocation of Oxaliplatin- or Gemcitabine-based Chemotherapy by Standard Clinical Criteria or by a Transcriptomic Treatment Specific Stratification Signature

AI 简述这是一项3期试验，在德国和瑞典研究基于转录组分类的化疗分配用于切除胰腺导管腺癌。

?

适用疾病: Pancreatic Ductal Adenocarcinoma
干预: Oxaliplatin，Irinotecan，Folinic acid，5-fluorouracil
地点: Germany，Sweden
申办方: John Neoptolemos

即将招募 Phase 2 药物其他

ClinicalTrials.gov NCT07028424

PANORAMIX : Optimizing 1st-line NALIRIFOX and Exploring Microbiota's Role in 2nd Line Pancreatic Cancer Treatment

AI 简述这是一项II期试验，研究NALIRIFOX方案用于一线胰腺癌，并在二线探索微生物组作用。

?

适用疾病: PDAC - Pancreatic Ductal Adenocarcinoma
干预: Nal-IRI，Ciprofloxacin，Paclitaxel，Gemcitabine
地点: France
申办方: GERCOR - Multidisciplinary Oncology Cooperative Group

即将招募 Phase 2 联合产品放疗

ClinicalTrials.gov NCT07097064

Evaluation of the Stereotactic MR-guided Adaptive Radiotherapy for Locally Advanced Pancreatic Cancers

AI 简述这是一项2期试验，比较MRI引导立体定向放射治疗与标准放化疗用于局部晚期胰腺癌，在法国开展。

?

适用疾病: Locally Advanced Pancreatic Adenocarcinoma
干预: standard radiotherapy with chemotherapy，MRI-guided adaptive stereotactic radiotherapy (SMART)
地点: France
申办方: Institut du Cancer de Montpellier - Val d'Aurelle

即将招募 Phase 1, Phase 2 联合产品

ClinicalTrials.gov NCT07477418

PDAC Regression and Intraoperative Surgical Margin With Neoadjuvant TAMP (PRISM-TAMP)

AI 简述这是一项I/II期试验，研究吉西他滨经动脉微灌注用于交界可切除胰腺导管腺癌。

?

适用疾病: Pancreatic Ductal Adenocarcinoma (PDAC)；Borderline Resectable Pancreatic Cancer；Pancreatic Neoplasms
干预: Gemcitabine Delivered by Transarterial Microperfusion
地点: United States
申办方: University of Vermont

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07565155

Lorigerlimab (MGD019) in Patients With Pancreatic Adenocarcinoma and Homologous Recombination Deficiency

AI 简述这是一项2期试验，研究Lorigerlimab用于胰腺癌伴同源重组缺陷，在美国开展。

?

适用疾病: Pancreatic Adenocarcinoma；Homologous Recombination Deficiency
干预: Lorigerlimab
地点: United States
申办方: Peter Hosein, MD

即将招募 Phase 1, Phase 2 药物手术/操作

ClinicalTrials.gov NCT07594626

BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP Deletion

AI 简述这是一项I/II期试验，研究PRMT5抑制剂BMS-986504联合培美曲塞用于MTAP缺失的转移性实体瘤。

?

适用疾病: Metastatic Biliary Tract Carcinoma；Metastatic Colon Carcinoma；Metastatic Esophageal Carcinoma
干预: Biospecimen Collection，Computed Tomography，Pemetrexed，PRMT5 Inhibitor BMS-986504
地点: United States
申办方: Northwestern University

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07616362

Personalize (Signature Driven) Neoadjuvant Chemotherapy Trial for Patients With Resectable Borderline Pancreatic Ductal Adenocarcinoma.

AI 简述这是一项II期试验，研究个体化新辅助化疗用于可切除交界性胰腺导管腺癌，在法国开展。

?

适用疾病: Borderline Resectable Pancreatic Ductal Adenocarcinoma
干预: Nab paclitaxel / gemcitabine，mFOLFIRINOX
地点: France
申办方: Federation Francophone de Cancerologie Digestive

即将招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT07665684

Samuraciclib in Combination With Gemcitabine/Nab-Paclitaxel in Patients With Metastatic Basal-Like Pancreatic Cancer

AI 简述这是一项I/II期试验，研究Samuraciclib联合吉西他滨/白蛋白紫杉醇用于转移性基底样胰腺癌。

?

适用疾病: Pancreas Ductal Adenocarcinoma；Pancreas Cancer, Metastatic；Pancreatic Adenocarcinoma Metastatic
干预: Samuraciclib + Gemcitabine & Nab-Paclitaxel
地点: Canada
申办方: University Health Network, Toronto

即将招募 Phase 1, Phase 2 生物制剂

ClinicalTrials.gov NCT07670312

Evaluation of XYA02 in Patients With Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究XYA02用于晚期实体瘤，包括非小细胞肺癌、卵巢癌等。在澳大利亚开展。

?

适用疾病: MUC1-expressing Advanced, Relapsed and/or Refractory Solid Tumors；Non-Small Cell Lung Cancer；Ovarian Cancer
干预: XYA02
地点: Australia
申办方: XYone Therapeutics, Inc

正在招募 Phase 1

NCI NCT02433626 / NCI-2015-01738

Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies

AI 简述这是一项I期试验，研究COTI-2单药或联合治疗用于复发性晚期卵巢癌等恶性肿瘤。

?

适用疾病: Stage III Primary Peritoneal Cancer；Stage IIIA Primary Peritoneal Cancer；Stage IIIB Primary Peritoneal Cancer
干预: 未列出
地点: United States
申办方: Critical Outcome Technologies Inc.

正在招募 Phase 1

NCI NCT02600949 / NCI-2016-00015

Personalized Peptide Vaccine in Treating Patients with Advanced Pancreatic Cancer or Colorectal Cancer

AI 简述这是一项I期试验，研究个性化肽疫苗用于晚期胰腺癌或结直肠癌，在美国开展。

?

适用疾病: Stage IV Colorectal (Colon or Rectal) Cancer；Stage IV Pancreatic Cancer；Metastatic Pancreatic Ductal Adenocarcinoma
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

正在招募 Phase 1

NCI NCT03098160 / NCI-2017-00995

Immunotherapy Study of Evofosfamide in Combination With Ipilimumab

AI 简述这是一项I期试验，研究Evofosfamide联合Ipilimumab用于多种晚期实体瘤。

?

适用疾病: Advanced Malignant Solid Tumor；Castration-Resistant Prostate Cancer；Head and Neck Squamous Cell Carcinoma
干预: 未列出
地点: United States
申办方: Threshold Pharmaceuticals

正在招募 Phase 1

NCI NCT03076372 / NCI-2017-01170

A Study Evaluating MM-310 in Patients With Solid Tumors

AI 简述这是一项I期试验，研究MM-310用于多种晚期实体瘤，在美国开展。

?

适用疾病: Malignant Solid Tumor；Prostate Adenocarcinoma；Non-Small Cell Lung Cancer
干预: 未列出
地点: United States
申办方: Merrimack Pharmaceuticals

正在招募 Phase 1

NCI NCT02675946 / NCI-2018-00241

CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)

AI 简述这是一项I期试验，研究CGX1321单用或联合Pembrolizumab或Encorafenib+Cetuximab用于晚期实体瘤和晚期胃肠道肿瘤。

?

适用疾病: Stage IIIA Esophageal Cancer；Stage IIIB Esophageal Cancer；Stage IIIC Esophageal Cancer
干预: 未列出
地点: United States
申办方: Curegenix Inc.

正在招募 Phase 1

NCI NCT03129139 / NCI-2018-00874

A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors

AI 简述这是一项I期试验，研究Minnelide胶囊单用或联合白蛋白紫杉醇用于晚期实体瘤，在美国开展。

?

适用疾病: Advanced Malignant Solid Tumor；Stage III Gastric (Stomach) Cancer；Stage IV Gastric (Stomach) Cancer
干预: 未列出
地点: United States
申办方: Minneamrita Therapeutics LLC

正在招募 Phase 1

NCI NCT03652428 / NCI-2018-03549

Nab-Paclitaxel, Gemcitabine, and Hypofractionated Ablative Proton Therapy in Treating Patients with Locally Advanced Pancreatic Cancer

AI 简述这是一项I期试验，研究白蛋白紫杉醇、吉西他滨和大分割质子治疗用于局部晚期胰腺癌。

?

适用疾病: Stage III Pancreatic Cancer；Locally Advanced Pancreatic Adenocarcinoma
干预: 未列出
地点: United States
申办方: University of Maryland/Greenebaum Cancer Center

正在招募 Phase 1

NCI NCT03715933 / NCI-2018-03556

Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas

AI 简述一项I期试验，研究INBRX-109联合伊立替康等用于晚期实体瘤包括肉瘤，在美国、法国等地开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Unresectable Solid Tumor；Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Inhibrx Biosciences, Inc

正在招募 Phase 1

NCI NCT03943004 / NCI-2019-04697

Trial of DFP-14927 in Advanced Solid Tumors

AI 简述这是一项I期试验，研究DFP-14927用于晚期实体瘤。

?

适用疾病: Refractory Malignant Solid Tumor；Refractory Pancreatic Carcinoma；Recurrent Gastroesophageal Junction Adenocarcinoma
干预: 未列出
地点: United States
申办方: Delta-Fly Pharma, Inc.

正在招募 Phase 1

NCI NCT04429542 / NCI-2020-04796

Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors

AI 简述这是一项I期试验，研究BCA101单药及联合治疗用于EGFR驱动的晚期实体瘤。

?

适用疾病: Advanced Malignant Solid Tumor；Non-Small Cell Squamous Lung Cancer；Stage III Head and Neck Squamous Cell Cancer
干预: 未列出
地点: United States
申办方: Bicara Therapeutics

正在招募 O

NCI NCT04930991 / NCI-2021-12551

High-Dose Omeprazole for the Treatment of Patients with Pancreatic Cancer before Surgery, OMEPRAZOLEPANC Trial

AI 简述这是一项0期试验，研究高剂量奥美拉唑用于可切除胰腺癌患者的术前治疗。

?

适用疾病: Resectable Pancreatic Adenocarcinoma；Malignant Exocrine Pancreas Neoplasm；Pancreatic Adenocarcinoma
干预: 未列出
地点: United States
申办方: University of Oklahoma Health Sciences Center

正在招募 Phase 1

NCI NCT05274048 / NCI-2022-05652

Neratinib and Trastuzumab Deruxtecan for the Treatment of HER2 Overexpressing Unresectable or Metastatic Gastrointestinal Cancer

AI 简述这是一项I期试验，研究Neratinib联合Fam-Trastuzumab Deruxtecan用于晚期胃食管癌。

?

适用疾病: Unresectable Esophageal Carcinoma；Stage III Esophageal Adenocarcinoma；Stage IV Esophageal Adenocarcinoma
干预: 未列出
地点: United States
申办方: Fox Chase Cancer Center

正在招募 Phase 1

NCI NCT05382559 / NCI-2022-09147

A Study of ASP3082 in Adults With Advanced Solid Tumors

AI 简述这是一项I期试验，研究ASP3082用于成人晚期实体瘤。在美国开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Locally Advanced Malignant Solid Tumor；Stage II Pancreatic Cancer
干预: 未列出
地点: United States
申办方: Astellas Pharma US Inc

正在招募阶段未标明

NCI NCT05764720 / NCI-2023-02447

Stereotactic Adaptive Radiation Therapy of Borderline Resectable Pancreatic Cancer an Individualized Approach

AI 简述这是一项试验，研究立体定向自适应放疗用于交界可切除或局部晚期胰腺癌。在美国开展。

?

适用疾病: Stage III Pancreatic Cancer；Locally Advanced Pancreatic Adenocarcinoma；Borderline Resectable Pancreatic Ductal Adenocarcinoma
干预: 未列出
地点: United States
申办方: Varian, a Siemens Healthineers Company

正在招募 Phase 1

NCI NCT05989724 / NCI-2023-08586

A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors

AI 简述这是一项I期试验，研究SON-DP用于标准治疗失败的晚期实体瘤，在美国开展。

?

适用疾病: Malignant Solid Tumor；Stage IV Colorectal (Colon or Rectal) Cancer；Stage IV Pancreatic Cancer
干预: 未列出
地点: United States
申办方: Qurgen Inc.

正在招募 Phase 1

NCI NCT05932862 / NCI-2023-10500

A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors

AI 简述这是一项I期试验，研究XL309单药或联合治疗用于晚期实体瘤，在美国开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Locally Advanced Malignant Solid Tumor；Stage II Pancreatic Cancer
干预: 未列出
地点: United States
申办方: Exelixis Inc

正在招募 Phase 1

NCI NCT06693986 / NCI-2024-02284

A Modified Conditionally Replicative Adenovirus Vector (RGDCRAdCOX2F) for the Treatment of Pancreatic Cancer

AI 简述这是一项1期试验，研究改造的条件复制型腺病毒载体用于胰腺癌。

?

适用疾病: Stage III Pancreatic Cancer；Locally Advanced Pancreatic Adenocarcinoma
干预: 未列出
地点: United States
申办方: University of Minnesota/Masonic Cancer Center

正在招募 Phase 1

NCI NCT06220864 / NCI-2024-03474

SNV1521 in Participants With Advanced Solid Tumors

AI 简述这是一项I期试验，研究SNV1521用于多种晚期实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Metastatic Castration-Resistant Prostate Carcinoma
干预: 未列出
地点: United States
申办方: Synnovation Therapeutics, Inc.

正在招募 Phase 1

NCI NCT06158139 / NCI-2024-03897

Chimeric Antigen Receptor (CAR) T-cell Therapy with iC9-CAR.B7-H3 T-cells for the Treatment of Refractory Pancreatic Ductal Adenocarcinoma

AI 简述这是一项I期试验，研究iC9-CAR.B7-H3 T细胞用于难治性胰腺导管腺癌，在美国开展。

?

适用疾病: Stage IV Pancreatic Cancer；Metastatic Pancreatic Ductal Adenocarcinoma；Refractory Pancreatic Ductal Adenocarcinoma
干预: 未列出
地点: United States
申办方: UNC Lineberger Comprehensive Cancer Center

正在招募 Phase 1

NCI NCT06242470 / NCI-2024-04298

A Study of MGC026 in Participants With Advanced Solid Tumors

AI 简述这是一项I期试验，研究MGC026用于晚期实体瘤患者，在美国、澳大利亚、英国等地开展。

?

适用疾病: Recurrent Malignant Solid Tumor；Metastatic Malignant Solid Tumor；Recurrent Lung Non-Squamous Non-Small Cell Carcinoma
干预: 未列出
地点: United States
申办方: MacroGenics Inc

正在招募 Phase 1

NCI NCT06205849 / NCI-2024-04756

Intra-Tumoral Mitazalimab with Irreversible Electroporation for the Treatment of Locally Advanced Pancreas Cancer

AI 简述这是一项I期试验，研究瘤内Mitazalimab联合不可逆电穿孔用于局部晚期胰腺癌。

?

适用疾病: Stage II Pancreatic Cancer；Locally Advanced Pancreatic Ductal Adenocarcinoma
干预: 未列出
地点: United States
申办方: UC San Diego Moores Cancer Center

正在招募 Phase 1

NCI NCT06400472 / NCI-2024-05353

A Study of LY4170156 in Participants With Selected Advanced Solid Tumors

AI 简述这是一项I期试验，研究LY4170156联合其他药物用于晚期实体瘤，在美国、澳大利亚等地开展。

?

适用疾病: Advanced Malignant Solid Tumor；Stage III Colorectal (Colon or Rectal) Cancer；Stage IV Colorectal (Colon or Rectal) Cancer
干预: 未列出
地点: United States
申办方: Eli Lilly and Company

正在招募 Phase 1

NCI NCT06384352 / NCI-2024-07039

Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors

AI 简述这是一项I期试验，研究YL211用于晚期实体瘤，在美国开展。

?

适用疾病: Advanced Malignant Solid Tumor；Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8；Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
干预: 未列出
地点: United States
申办方: MediLink Therapeutics (Suzhou) Co., Ltd.

正在招募 Phase 1

NCI NCT06576037 / NCI-2024-07312

CBP-1019 with FOLFOX with or without Bevacizumab, Pembrolizumab, or Enzalutamide for the Treatment of Metastatic Solid Tumors of Epithelial Origin

AI 简述这是一项I期试验，研究CBP-1019联合FOLFOX并用或不用其他药物治疗转移性实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Castration-Resistant Prostate Cancer；Stage IV Colorectal (Colon or Rectal) Cancer
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

正在招募 Phase 1

NCI NCT06582017 / NCI-2024-07730

Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma

AI 简述这是一项I期试验，研究QXL138AM用于实体瘤和多发性骨髓瘤。在美国开展。

?

适用疾病: Metastatic Urothelial Cancer；Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Nammi Therapeutics Inc

正在招募 Phase 1

NCI NCT05005403 / NCI-2025-01100

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

AI 简述这是一项I期试验，研究Azirkitug单药或联合其他药物用于非小细胞肺癌等实体瘤，在美国、加拿大等地开展。

?

适用疾病: High Grade Ovarian Serous Adenocarcinoma；Advanced Malignant Solid Tumor；Stage III Head and Neck Squamous Cell Cancer
干预: 未列出
地点: United States
申办方: Abbvie

正在招募 Phase 1

NCI NCT06764771 / NCI-2025-02616

A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors

AI 简述这是一项I期试验，在美国研究BMS-986488单药或联合用于晚期恶性实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Stage III Colorectal (Colon or Rectal) Cancer
干预: 未列出
地点: United States
申办方: Bristol-Myers Squibb

正在招募 Phase 1

NCI NCT06823167 / NCI-2025-03470

A Phase 1 Study of IM-1021 in Participants With Advanced Cancer

AI 简述这是一项I期试验，在美国开展，研究IM-1021用于多种晚期实体瘤。

?

适用疾病: Recurrent Fallopian Tube Cancer；Recurrent Primary Peritoneal Cancer；Recurrent Lung Non-Squamous Non-Small Cell Carcinoma
干预: 未列出
地点: United States
申办方: Immunome, Inc.

正在招募 Phase 1

NCI NCT06804824 / NCI-2025-04592

A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors

AI 简述这是一项I期试验，研究VVD-159642用于晚期实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Stage III Colorectal (Colon or Rectal) Cancer；Stage IV Colorectal (Colon or Rectal) Cancer
干预: 未列出
地点: United States
申办方: Vividion Therapeutics, Inc.

正在招募阶段未标明

NCI NCT06698458 / NCI-2025-07104

Alpha Radiation Emitters (DaRT) With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer

AI 简述这是一项试验，研究放疗（DaRT）联合化疗用于局部晚期和转移性胰腺癌。

?

适用疾病: Stage III Pancreatic Cancer；Stage IV Pancreatic Cancer；Locally Advanced Pancreatic Adenocarcinoma
干预: 未列出
地点: United States
申办方: Alpha Tau Medical LTD.

正在招募 Phase 1

NCI NCT07207707 / NCI-2025-07562

A Study to Investigate the Safety and Efficacy of KQB548 in Participants With Advanced Solid Malignancies

AI 简述这是一项I期试验，研究KQB548用于晚期实体瘤。在美国开展。

?

适用疾病: Advanced Malignant Solid Tumor；Stage III Colorectal (Colon or Rectal) Cancer；Stage IV Colorectal (Colon or Rectal) Cancer
干预: 未列出
地点: United States
申办方: Kumquat Biosciences Inc.

正在招募 Phase 1

NCI NCT07382544 / NCI-2025-09342

PRMT5 Inhibition with BMS-986504 and PARP Inhibition with Olaparib for the Treatment of Advanced and Metastatic Solid Tumors with MTAP Loss

AI 简述这是一项I期试验，在美国开展，研究PRMT5抑制剂BMS-986504联合PARP抑制剂奥拉帕利用于MTAP缺失的晚期或转移性实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Stage II Pancreatic Cancer
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

正在招募 Phase 1

NCI NCT07141706 / NCI-2025-09675

A Study of DB-1317 in Selected Advanced/Metastatic Solid Tumors

AI 简述这是一项I期试验，在美国开展，研究DB-1317用于晚期/转移性实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Stage III Gastric (Stomach) Cancer
干预: 未列出
地点: United States
申办方: DualityBio Inc.

正在招募 Phase 1

NCI NCT07127874 / NCI-2026-00071

A Study of PHN-012 in Patients With Advanced Solid Tumors

AI 简述这是一项I期试验，研究PHN-012用于晚期实体瘤，在美国和西班牙开展。

?

适用疾病: Stage III Colorectal (Colon or Rectal) Cancer；Stage IV Colorectal (Colon or Rectal) Cancer；Stage II Pancreatic Cancer
干预: 未列出
地点: United States
申办方: Pheon Therapeutics

正在招募 Phase 1

NCI NCT07252479 / NCI-2026-00268

Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations

AI 简述这是一项I期试验，研究RAS抑制剂用于携带RAS突变的晚期或转移性实体瘤，于美国开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Refractory Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Adlai Nortye Biopharma Co., Ltd.

正在招募阶段未标明

NCI NCT07340151 / NCI-2026-00871

Surgical Resection after Chemotherapy for the Treatment of Pulmonary or Hepatic Oligometastatic Pancreatic Cancer

AI 简述这是一项试验，研究化疗后手术切除用于胰腺癌肺或肝寡转移。

?

适用疾病: Stage IV Pancreatic Cancer；Oligometastatic Pancreatic Ductal Adenocarcinoma；Metastatic Malignant Neoplasm to the Lung
干预: 未列出
地点: United States
申办方: University of Texas Health Science Center at San Antonio

正在招募 Phase 1

NCI NCT07166601 / NCI-2026-01622

M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors

AI 简述这是一项I期试验，在United States开展，研究M0324单药或联合帕博利珠单抗或化疗用于晚期实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Refractory Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: EMD Serono Research & Development Institute, Inc.

正在招募 Phase 1

NCI NCT05458219 / NCI-2026-02256

A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors

AI 简述这是一项I期试验，研究IBI343用于局部晚期不可切除或转移性实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8；Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
干预: 未列出
地点: United States
申办方: Innovent Biologics (Suzhou) Co. Ltd.

正在招募 Phase 1

NCI NCT05841563 / NCI-2026-03026

Clinical Trial of PM54 in Advanced Solid Tumors Patients.

AI 简述这是一项I期试验，在美国开展，研究PM54用于晚期实体瘤患者。

?

适用疾病: Advanced Malignant Solid Tumor；Stage III Esophageal Adenocarcinoma；Stage IV Esophageal Adenocarcinoma
干预: 未列出
地点: United States
申办方: PharmaMar SA

正在招募 Phase 1

NCI NCT07541573 / NCI-2026-03508

A Camelid Nanobody B7-H3 Tri-Specific Killer Engager (GTB-5550) for the Treatment of Advanced Solid Tumors that Failed Prior Therapy

AI 简述这是一项I期试验，研究GTB-5550用于既往治疗失败的晚期实体瘤，在美国开展。

?

适用疾病: Recurrent Fallopian Tube Cancer；Recurrent Primary Peritoneal Cancer；Recurrent Bladder Urothelial Cancer
干预: 未列出
地点: United States
申办方: University of Minnesota/Masonic Cancer Center

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT03454035 / NCI-2017-02445

Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors

AI 简述这是一项I期试验，研究Ulixertinib和Palbociclib用于晚期胰腺癌和其他实体瘤。

?

适用疾病: Tumor, Solid；Pancreatic Cancer；Melanoma
干预: Ulixertinib，Palbociclib
地点: United States
申办方: UNC Lineberger Comprehensive Cancer Center

正在招募阶段未标明放疗

ClinicalTrials.gov NCT03704662

Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable or Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma

AI 简述一项比较立体定向放疗与术前分割放化疗用于可切除或交界可切除胰腺癌的试验，在美国开展。

?

适用疾病: Pancreatic Cancer
干预: Stereotactic Body Radiation Therapy，Preoperative Fractionated Radiation Therapy and Chemotherapy
地点: United States
申办方: Medical College of Wisconsin

正在招募 Phase 1 生物制剂

ClinicalTrials.gov / NCI NCT03740256 / NCI-2021-01066

Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors

AI 简述这是一项I期试验，研究CAdVEC用于HER2阳性晚期实体瘤，在美国开展。

?

适用疾病: Bladder Cancer；Head and Neck Squamous Cell Carcinoma；Cancer of the Salivary Gland
干预: CAdVEC
地点: United States
申办方: Baylor College of Medicine

正在招募 EARLY / Phase 1 生物制剂药物

ClinicalTrials.gov / NCI NCT04005690 / NCI-2019-01265

Targeted Pathway Inhibition in Patients With Pancreatic Cancer

AI 简述这是一项早期I期试验，研究多种靶向药物用于胰腺癌。

?

适用疾病: Locally Advanced Pancreatic Ductal Adenocarcinoma；Metastatic Pancreatic Ductal Adenocarcinoma；Stage II Pancreatic Cancer AJCC v8
干预: Cobimetinib，Olaparib，Onvansertib，Azenosertib
地点: United States
申办方: OHSU Knight Cancer Institute

正在招募阶段未标明手术/操作

ClinicalTrials.gov NCT04037007

Efficacy of Fistulotomy for Biliary Cannulation

AI 简述这是一项非随机试验，比较瘘管切开术与常规导丝插管用于胆管插管，在墨西哥开展。

?

适用疾病: Cholangiocarcinoma；Choledocholithiasis; Cholangitis；Pancreatic Cancer
干预: Fistulotomy - High experienced.，Fistulotomy - Low experienced.，Conventional (guidewire) cannulation- High experienced，Conventional (guidewire) cannulation - Low experienced
地点: Mexico
申办方: Coordinación de Investigación en Salud, Mexico

正在招募 Phase 1 生物制剂药物其他

ClinicalTrials.gov NCT04119024

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

AI 简述这是一项I期试验，研究基因修饰免疫细胞用于晚期黑色素瘤或转移性实体瘤。

?

适用疾病: Metastatic Malignant Solid Neoplasm；Metastatic Melanoma；Pathologic Stage IIIC Cutaneous Melanoma AJCC v8
干预: Biopsy，Biospecimen Collection，Computed Tomography，Cyclophosphamide
地点: United States
申办方: Anusha Kalbasi

正在招募 Phase 1 器械药物

ClinicalTrials.gov / NCI NCT04150042 / NCI-2021-00604

SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells

AI 简述这是一项I期试验，研究Melphalan和BCNU联合自身干细胞移植用于转移性胰腺癌。

?

适用疾病: Pancreatic Adenocarcinoma Metastatic；BRCA1 Mutation；BRCA2 Mutation
干预: Melphalan，BCNU，Vitamin B12B，Vitamin C
地点: United States
申办方: General Oncology, Inc.

正在招募 Phase 1 生物制剂

ClinicalTrials.gov / NCI NCT04157127 / NCI-2025-05647

Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma

AI 简述这是一项I期试验，研究Th-1树突细胞免疫疗法联合标准化疗用于胰腺腺癌。

?

适用疾病: Pancreatic Adenocarcinoma；Pancreatic Cancer；Pancreatic Adenosquamous Carcinoma
干预: Autologous DC Therapy
地点: United States
申办方: Diakonos Oncology Corporation

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT04222413 / NCI-2020-00306

Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors

AI 简述这是一项I期试验，研究Metarrestin（ML-246）用于转移性实体瘤，包括胰腺癌和乳腺癌。

?

适用疾病: Advanced Solid Tumors；Metastatic Pancreatic Cancer；Pediatric Solid Tumor
干预: Metarrestin
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT04361708 / NCI-2020-13964

Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies

AI 简述这是一项I期试验，研究伊立替康联合5-FU、亚叶酸、奥沙利铂和多西他赛用于胰腺癌或胃食管交界腺癌。

?

适用疾病: Pancreatic Adenocarcinoma；Gastroesophageal Junction Adenocarcinoma；Adenocarcinoma
干预: Oxaliplatin，Docetaxel，Leucovorin，Irinotecan
地点: United States
申办方: University of Chicago

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT04389632 / NCI-2020-03931

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

AI 简述这是一项I期试验，研究Sigvotatug Vedotin用于晚期实体瘤，在美国、法国、韩国、西班牙等地开展。

?

适用疾病: Carcinoma, Non-Small Cell Lung；Squamous Cell Carcinoma of Head and Neck；HER2 Negative Breast Neoplasms
干预: sigvotatug vedotin，pembrolizumab，cisplatin，carboplatin
地点: United States，France，South Korea，Spain 等 3 个
申办方: Seagen, a wholly owned subsidiary of Pfizer

正在招募阶段未标明手术/操作

ClinicalTrials.gov NCT04571294

Para-aortic Lymphnodes Removal During Upfront Pancreaticoduodenectomy

AI 简述这是一项NA期试验，研究胰十二指肠切除术中清扫腹主动脉旁淋巴结用于胰腺癌，在意大利开展。

?

适用疾病: Pancreas Cancer；Pancreaticoduodenal Lymphadenopathy；Pancreas Adenocarcinoma
干预: removal of para-aortic lymphnodes (PALN)
地点: Italy
申办方: Humanitas Hospital, Italy

正在招募 EARLY / Phase 1 药物

ClinicalTrials.gov / NCI NCT04665947 / NCI-2020-13843

First-in-human Study of the Theranostic Pair [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G in Pancreatic Cancer

AI 简述这是一项早期I期试验，研究[68Ga]Ga DOTA-5G和[177Lu]Lu DOTA-ABM-5G用于胰腺癌。

?

适用疾病: Metastatic Pancreatic Cancer；Locally Advanced Pancreatic Adenocarcinoma；Stage II Pancreatic Cancer
干预: [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G.
地点: United States
申办方: University of California, Davis

正在招募阶段未标明放疗

ClinicalTrials.gov NCT04881487

Additional Treatment for Isolated Local Pancreatic Cancer Recurrence Using Stereotactic Body Radiation Therapy

AI 简述这是一项试验，评估立体定向体部放射治疗用于局部复发性胰腺癌。在荷兰开展。

?

适用疾病: Recurrent Pancreatic Ductal Adenocarcinoma
干预: Additional stereotactic body radiation therapy
地点: Netherlands
申办方: UMC Utrecht

正在招募 Phase 1 药物

ClinicalTrials.gov NCT04999761

AB122 Platform Study

AI 简述这是一项I期试验，研究AB122联合TAS-116、TAS-120、TAS-115用于晚期或转移性实体瘤，在日本开展。

?

适用疾病: Advanced or Metastatic Solid Tumor；Pancreatic Ductal Adenocarcinoma；Colorectal Cancer
干预: AB122，AB122，TAS-116，AB122
地点: Japan
申办方: Taiho Pharmaceutical Co., Ltd.

正在招募 Phase 1 生物制剂药物

ClinicalTrials.gov / NCI NCT05076760 / NCI-2022-02030

MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors

AI 简述这是一项I期试验，研究MEM-288溶瘤病毒单用或联合标准治疗用于晚期实体瘤。

?

适用疾病: Solid Tumor；Advanced Cancer；Metastatic Cancer
干预: MEM-288 Intratumoral Injection，Nivolumab，Docetaxel
地点: United States
申办方: Memgen, Inc.

正在招募阶段未标明其他手术/操作

ClinicalTrials.gov NCT05132244

Monitoring and Managing Glucose Levels in People With Pancreatic Cancer

AI 简述这是一项试验，研究使用连续血糖监测管理胰腺癌患者的血糖水平，在加拿大开展。

?

适用疾病: Pancreatic Cancer；PDAC - Pancreatic Ductal Adenocarcinoma；Hyperglycemia
干预: Endocrinologist-directed target blood glucose level 4-10 mmol/L using data from a continuous glucose monitor (CGM)，Standard Care
地点: Canada
申办方: British Columbia Cancer Agency

正在招募 Phase 1 放疗

ClinicalTrials.gov NCT05141513

Intraoperative Radiation Therapy After Stereotactic Body Radiation Therapy and Chemotherapy in Treatment of Pancreatic Adenocarcinoma

AI 简述这是一项I期试验，研究立体定向放疗和化疗后行术中放疗用于胰腺腺癌，在美国开展。

?

适用疾病: Pancreatic Cancer
干预: High Dose Rate Brachytherapy (HDR) Intraoperative Radiation Therapy (IORT)
地点: United States
申办方: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

正在招募 Phase 1 药物

ClinicalTrials.gov NCT05245500

Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

AI 简述这是一项I期试验，研究MRTX1719用于MTAP缺失的实体瘤，包括间皮瘤、非小细胞肺癌等。

?

适用疾病: Mesothelioma；Non Small Cell Lung Cancer；Malignant Peripheral Nerve Sheath Tumors
干预: MRTX1719
地点: United States
申办方: Bristol-Myers Squibb

正在招募 Phase 1 药物

ClinicalTrials.gov NCT05277766

Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer

AI 简述这是一项I期试验，研究腹腔内气溶胶纳米脂质体伊立替康用于胃肠道癌腹膜转移，在比利时开展。

?

适用疾病: Peritoneal Carcinomatosis；Peritoneal Metastases；Colorectal Cancer
干预: PIPAC with Nal-IRI
地点: Belgium
申办方: University Hospital, Ghent

正在招募 Phase 1 药物

ClinicalTrials.gov NCT05403554

A Study of NI-1801 in Patients with Mesothelin Expressing Solid Cancers

AI 简述这是一项I期试验，研究NI-1801单药或联合用药用于间皮素表达阳性的实体瘤（卵巢癌、三阴性乳腺癌等），在法国、意大利开展。

?

适用疾病: Epithelial Ovarian Cancer；Triple Negative Breast Cancer；Non-squamous Non-small-cell Lung Cancer
干预: Biological NI-1801，NI-1801 in combination with anti-PD1 (Pembrolizumab)，NI-1801 in combination with paclitaxel，Paclitaxel
地点: France，Italy
申办方: Light Chain Bioscience - Novimmune SA

正在招募阶段未标明器械放疗

ClinicalTrials.gov NCT05679674

Stereotactic Body Radiation and Tumor Treating Fields for Locally Advanced Pancreas Cancer

AI 简述这是一项试验，研究立体定向体部放疗联合肿瘤电场治疗用于局部晚期胰腺癌。

?

适用疾病: Pancreas Cancer；Locally Advanced；Locally Advanced Pancreatic Adenocarcinoma
干预: Stereotactic Ablative Body Radiation (SABR)，Tumor Treating Fields (TTF)
地点: United States
申办方: Baptist Health South Florida

正在招募 Phase 1 药物手术/操作

ClinicalTrials.gov NCT05687123

Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors

AI 简述这是一项I期试验，研究Sunitinib联合Lutetium Lu 177 Dotatate用于胰腺神经内分泌肿瘤。在美国、加拿大等地开展。

?

适用疾病: Metastatic Pancreatic Neuroendocrine Tumor；Pancreatic Neoplasm；Stage III Pancreatic Neuroendocrine Tumor AJCC v8
干预: Biospecimen Collection，Computed Tomography，Lutetium Lu 177 Dotatate，Magnetic Resonance Imaging
地点: United States，Canada
申办方: National Cancer Institute (NCI)

正在招募 Phase 1 器械药物

ClinicalTrials.gov NCT05723107

EUS RFA for Treatment of Pancreatic Ductal Adenocarcinoma (PDAC)

AI 简述这是一项I期试验，研究超声内镜引导射频消融联合化疗用于胰腺癌。

?

适用疾病: Pancreatic Cancer
干预: Chemotherapy，Endoscopic Ultrasound-Guided Radiofrequency Ablation (EUS-RFA)
地点: United States
申办方: NYU Langone Health

正在招募 Phase 1 药物

ClinicalTrials.gov NCT05759923

First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 in Patients with Selected Advanced And/or Metastatic Solid Tumours

AI 简述这是一项1期试验，研究OATD-02用于晚期及/或转移性实体瘤。

?

适用疾病: Advanced Ovarian Carcinoma；Advanced Renal Cell Carcinoma；Advanced Pancreatic Carcinoma
干预: OATD-02
地点: Poland
申办方: Molecure S.A.

正在招募阶段未标明放疗

ClinicalTrials.gov NCT05837767

A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue

AI 简述这是一项临床试验，研究姑息放疗用于软组织转移的实体瘤。

?

适用疾病: Invasive Ductal Breast Carcinoma；Invasive Ductal Breast Carcinoma Stage IV；Lobular Breast Carcinoma
干预: Palliative radiotherapy
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 1 生物制剂

ClinicalTrials.gov / NCI NCT05877599 / NCI-2023-04428

A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

AI 简述这是一项I期试验，研究TP53 R175H靶向T细胞用于HLA-A*02:01阳性晚期实体瘤，在美国开展。

?

适用疾病: Non-small Cell Lung Cancer；Head and Neck Squamous Cell Carcinoma；Colorectal Carcinoma
干预: Autologous, engineered T Cells targeting TP53 R175H
地点: United States
申办方: AstraZeneca

正在招募 Phase 1 联合产品

ClinicalTrials.gov / NCI NCT05919238 / NCI-2024-08520

Padeliporfin VTP Treatment for Unresectable Pancreatic Adenocarcinoma

AI 简述这是一项I期试验，在美国开展，研究Padeliporfin血管靶向光动力疗法用于不可切除胰腺腺癌。

?

适用疾病: Locally Advanced Unresectable Pancreatic Adenocarcinoma；Stage III Pancreatic Cancer；Locally Advanced Pancreatic Adenocarcinoma
干预: Padeliporfin Vascular Targeted Photodynamic (VTP) therapy
地点: United States
申办方: Impact Biotech Ltd

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06026410 / NCI-2023-07364

KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

AI 简述这是一项I期试验，研究Darlifarnib联合Cabozantinib或Adagrasib用于晚期实体瘤。在美国、法国等地开展。

?

适用疾病: Solid Tumors With HRAS Alterations；Non Small Cell Lung Cancer (NSCLC)；Colorectal Cancer (CRC)
干预: Darlifarnib，Cabozantinib，Adagrasib
地点: United States，France，Germany，Italy 等 1 个
申办方: Kura Oncology, Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov NCT06040541

Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

AI 简述这是一项I期试验，研究RMC-9805用于KRAS G12D突变实体瘤。

?

适用疾病: Non-small Cell Lung Cancer (NSCLC)；Colorectal Cancer (CRC)；Pancreatic Ductal Adenocarcinoma (PDAC)
干预: RMC-9805，RMC-6236
地点: United States
申办方: Revolution Medicines, Inc.

正在招募 Phase 1 药物放疗

ClinicalTrials.gov / NCI NCT06141031 / NCI-2023-10168

Radiotherapy in Combination With TTI-101 in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma

AI 简述这是一项I期试验，研究TTI-101联合放疗用于交界可切除和局部晚期胰腺癌，在美国开展。

?

适用疾病: Pancreatic Cancer；Stage II Pancreatic Cancer；Locally Advanced Pancreatic Ductal Adenocarcinoma
干预: TTI-101，Stereotactic body radiation therapy
地点: United States
申办方: Washington University School of Medicine

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06182072 / NCI-2025-02847

ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC)

AI 简述这是一项I期试验，研究ProAgio联合吉西他滨和纳布紫杉醇用于胰腺导管腺癌。在美国开展。

?

适用疾病: Pancreatic Ductal Adenocarcinoma (PDAC)；Stage IV Pancreatic Cancer；Metastatic Pancreatic Ductal Adenocarcinoma
干预: ProAgio Dose Levels (DL) 1,2,3,4，Gemcitabine, nab paclitaxel
地点: United States
申办方: ProDa BioTech, LLC

正在招募 Phase 1 生物制剂

ClinicalTrials.gov / NCI NCT06218914 / NCI-2024-01226

Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

AI 简述这是一项I期试验，研究靶向KRAS G12D的T细胞疗法用于不可切除晚期实体瘤，在美国开展。

?

适用疾病: Non-small Cell Lung Cancer；Colorectal Carcinoma；Pancreatic Ductal Adenocarcinoma
干预: NT-112: Autologous, engineered T Cells targeting KRAS G12D，AZD0240: Autologous, engineered T Cells targeting KRAS G12D
地点: United States
申办方: AstraZeneca

正在招募 Phase 1 联合产品

ClinicalTrials.gov NCT06229496

Dose Escalation and Dose Expansion Study of GAS in Subjects With Metastatic Pancreatic Adenocarcinoma

AI 简述这是一项I期试验，研究GAS方案用于转移性胰腺腺癌。在台湾开展。

?

适用疾病: Metastatic Pancreatic Adenocarcinoma
干预: Gemcitabine 800mg/m2 + Nab-paclitaxel 100mg/m2 + S-1 (dose according to BSA)，Gemcitabine 800mg/m2 + Nab-paclitaxel 125mg/m2 + S-1 (dose according to BSA)，Gemcitabine 1000mg/m2 + Nab-paclitaxel 125mg/m2 + S-1 (dose according to BSA)
地点: Taiwan
申办方: Chang Gung Memorial Hospital

正在招募 Phase 1 药物

ClinicalTrials.gov NCT06393400

CHemotherapy and Stool Transplant in PDAC (CHASe-PDAC)

AI 简述这是一项I期试验，研究粪便微生物移植联合化疗用于不可切除或转移性晚期胰腺癌，在加拿大开展。

?

适用疾病: Unresectable or Metastatic Advanced Pancreatic Ductal Adenocarcinoma
干预: Fecal Microbiota Transplantation，PEG3350，Gemcitabine，nab-Paclitaxel
地点: Canada
申办方: John Lenehan

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06411691 / NCI-2025-01263

KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer

AI 简述这是一项I期试验，研究KRAS疫苗联合Balstilimab和Botensilimab用于IV期结直肠癌和胰腺导管癌，在美国开展。

?

适用疾病: Colorectal Cancer；Pancreatic Cancer；Stage IV Colorectal (Colon or Rectal) Cancer
干预: KRAS Vaccine with Poly-ICLC adjuvant，Balstilimab，Botensilimab
地点: United States
申办方: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

正在招募 Phase 1 药物

ClinicalTrials.gov NCT06440005

A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors

AI 简述这是一项I期试验，研究AGX101用于晚期实体瘤。

?

适用疾病: Cancer；Advanced Cancer；Locally Advanced Carcinoma
干预: AGX101
地点: United States
申办方: Angiex, Inc.

正在招募 Phase 1 药物手术/操作

ClinicalTrials.gov / NCI NCT06454383 / NCI-2024-04359

Gemcitabine and Leflunomide in Patients With Advanced Unresectable Pancreatic Cancer

AI 简述这是一项I期试验，研究吉西他滨和来氟米特用于晚期不可切除胰腺癌。

?

适用疾病: Advanced Pancreatic Adenocarcinoma；Stage III Pancreatic Cancer AJCC v8；Stage IV Pancreatic Cancer AJCC v8
干预: Biospecimen Collection，Cholestyramine，Computed Tomography，Diagnostic Imaging
地点: United States
申办方: City of Hope Medical Center

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06458712 / NCI-2025-05692

Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies

AI 简述这是一项I期试验，在美国、法国等地研究DSB2455用于晚期实体瘤。

?

适用疾病: Advanced Malignancies With Homologous Recombination Deficiency (HRD) (Breast, Ovarian, mCRPC, Pancreatic Ductal Adenocarcinoma (PDAC), Brain Metastases)；Advanced Malignant Solid Tumor；Stage II Pancreatic Cancer
干预: DSB2455
地点: United States，France，Hungary，Spain
申办方: Duke Street Bio Ltd

正在招募 Phase 1 药物

ClinicalTrials.gov NCT06533332

A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors

AI 简述这是一项I期试验，研究ERX-315用于晚期实体瘤，包括转移性乳腺癌、卵巢癌等，在澳大利亚开展。

?

适用疾病: Advanced Solid Tumor；Metastatic Breast Cancer；Metastatic Ovarian Cancer
干预: ERX-315
地点: Australia
申办方: EtiraRx Australia Pty Ltd

正在招募阶段未标明药物

ClinicalTrials.gov NCT06539806

Clinical Study Evaluating the Effect of Losartan

AI 简述这是一项评估Losartan对胰腺癌影响的临床研究，在埃及开展。

?

适用疾病: Pancreatic Cancer
干预: Losartan 50mg Tab
地点: Egypt
申办方: Tanta University

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06562192 / NCI-2024-08464

Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

AI 简述这是一项I期试验，研究[177Lu]Lu-NNS309用于胰腺癌、肺癌、乳腺癌和结直肠癌。

?

适用疾病: Pancreatic Ductal Adenocarcinoma；Non-small Cell Lung Cancer；HR+/HER2- Ductal and Lobular Breast Cancer
干预: [68Ga]Ga-NNS309，[177Lu]Lu-NNS309
地点: United States，Belgium，Canada，France 等 6 个
申办方: Novartis Pharmaceuticals

正在招募 Phase 1 联合产品

ClinicalTrials.gov / NCI NCT06639724 / NCI-2025-00369

Perioperative Fostamatinib With Gemcitabine and Nab-paclitaxel in Resectable Pancreatic Cancer

AI 简述这是一项I期试验，研究Fostamatinib联合吉西他滨和白蛋白紫杉醇围手术期治疗可切除胰腺癌。

?

适用疾病: Pancreatic Ductal Adenocarcinoma (PDAC)；Stage 0 Pancreatic Cancer；Stage I Pancreatic Cancer
干预: Fostamatinib in combination with chemotherapy (gemcitabine and nab-paclitaxel)
地点: United States
申办方: University of California, San Diego

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06648434 / NCI-2025-03602

MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma

AI 简述这是一项I期试验，研究Zunsemetinib联合mFOLFIRINOX用于转移性胰腺导管腺癌。

?

适用疾病: Metastatic Pancreatic Ductal Adenocarcinoma；Pancreatic Cancer；Cancer of the Pancreas
干预: Zunsemetinib，mFOLFIRINOX
地点: United States
申办方: Washington University School of Medicine

正在招募 Phase 1 药物

ClinicalTrials.gov NCT06663072

Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors

AI 简述这是一项I期试验，研究Fulvestrant联合Lu-DOTATATE用于晚期胰腺神经内分泌瘤。

?

适用疾病: Metastatic Pancreatic Neuroendocrine Tumor
干预: Fulvestrant，177Lu-DOTATATE
地点: United States
申办方: University of Chicago

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06673017 / NCI-2025-03238

PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)

AI 简述这是一项I期试验，研究PTM-101用于胰腺导管腺癌。

?

适用疾病: Pancreatic Ductal Adenocarcinoma；Borderline Resectable Pancreatic Adenocarcinoma；Locally Advanced Pancreatic Adenocarcinoma
干预: PTM-101
地点: United States
申办方: PanTher Therapeutics

正在招募阶段未标明药物放疗

ClinicalTrials.gov NCT06691425

Stereotactic Body Radiation Therapy for Inoperable Non-metastasized Pancreatic Adenocarcinoma

AI 简述这是一项试验，研究立体定向体部放疗联合化疗用于不可切除的非转移性胰腺癌，在比利时开展。

?

适用疾病: Non-metastasized Unresectable Pancreatic Carcinoma
干预: Stereotactic Body Radiation Therapy (SBRT)，Chemotherapy
地点: Belgium
申办方: Cancer Research Antwerp

正在招募 Phase 1 生物制剂

ClinicalTrials.gov / NCI NCT06723236 / NCI-2025-03571

A Study of MGC028 in Participants With Advanced Solid Tumors

AI 简述这是一项I期试验，在美国开展，研究MGC028用于晚期实体瘤。

?

适用疾病: Advanced Solid Tumors；NSCLC Adenocarcinoma；Cholangiocarcinoma
干预: MGC028
地点: United States
申办方: MacroGenics

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06756035 / NCI-2025-04725

CT-95 in Advanced Cancers Associated With Mesothelin Expression

AI 简述这是一项I期试验，研究CT-95用于间皮素表达的晚期实体瘤，包括卵巢癌、间皮瘤和胰腺癌。

?

适用疾病: Mesothelin-Expressing Tumors；Epithelial Ovarian Cancer；Malignant Pleural Mesothelioma, Advanced
干预: CT-95
地点: United States
申办方: Context Therapeutics Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov NCT06778863

A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

AI 简述这是一项I期试验，研究CLSP-1025用于p53 R175H突变实体瘤。

?

适用疾病: Advanced Solid Tumor；Unresectable Solid Tumor；Metastatic Solid Tumor
干预: CLSP-1025
地点: United States
申办方: Clasp Therapeutics, Inc.

正在招募阶段未标明手术/操作

ClinicalTrials.gov NCT06801899

ToPanc Trial: Survival After Total Versus Partial Pancreaticoduodenectomy for Adenocarcinoma of the Pancreatic Head, Distal Cholangiocarcinoma, and Ampullary Cancer

AI 简述这是一项试验，比较全胰腺切除术与部分胰十二指肠切除术用于胰腺癌。

?

适用疾病: Pancreatic Cancer
干预: Total pancreatectomy (TP)，Partial pancreaticoduodenectomy (PD)
地点: Germany，Switzerland
申办方: Insel Gruppe AG, University Hospital Bern

正在招募 Phase 1 药物

ClinicalTrials.gov NCT06835569

A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations

AI 简述这是一项I期试验，研究ALTA3263用于KRAS突变的晚期实体瘤，包括胰腺癌、非小细胞肺癌、结直肠癌等，在美国开展。

?

适用疾病: Cancer；PDAC - Pancreatic Ductal Adenocarcinoma；NSCLC (Non-small Cell Lung Cancer)
干预: ALTA3263，cetuximab，mFOLFOX6，Pembrolizumab
地点: United States
申办方: Alterome Therapeutics, Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06882746 / NCI-2025-03676

A Study to Test Different Doses of BI 765049 in People With Advanced Cancer of the Colon, Rectum, Stomach, or Pancreas

AI 简述这是一项I期试验，在美国研究BI 765049用于晚期结直肠癌、胃癌或胰腺癌。

?

适用疾病: Colorectal Carcinoma；Gastric Carcinoma；Pancreatic Ductal Adenocarcinoma
干预: BI 765049
地点: United States
申办方: Boehringer Ingelheim

正在招募 Phase 1 药物

ClinicalTrials.gov NCT06892054

Sotorasib Combined With First-line Chemotherapy for Advanced Pancreatic Adenocarcinoma

AI 简述这是一项I期试验，研究Sotorasib联合一线化疗用于晚期胰腺腺癌，在法国等地开展。

?

适用疾病: Pancreatic Adenocarcinoma
干预: Sotorasib, 960 mg, oral daily dose for 4 weeks (28 days)
地点: France，Spain
申办方: Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06896188 / NCI-2026-00159

9-ING-41 Combined With Retifanlimab, Plus Modified FOLFIRINOX for Patients With Advanced Pancreatic Adenocarcinoma (RiLEY)

AI 简述这是一项I期试验，研究Retifanlimab、化疗和9-ING-41用于晚期胰腺癌，在美国开展。

?

适用疾病: Pancreatic Adenocarcinoma；Stage III Pancreatic Cancer；Stage IV Pancreatic Cancer
干预: Retifanlimab，Chemotherapy，9-ING-41
地点: United States
申办方: Anwaar Saeed

正在招募 Phase 1 生物制剂

ClinicalTrials.gov NCT06910657

IDOV-Immune for Advanced Solid Tumors

AI 简述这是一项I期试验，研究IDOV-Immune用于晚期实体瘤，包括结直肠癌、胰腺癌等。在美国和澳大利亚开展。

?

适用疾病: Colorectal Cancer；Pancreatic Cancer；Melanoma
干预: IDOV-Immune (oncolytic vaccinia virus)
地点: United States，Australia
申办方: ViroMissile, Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06917079 / NCI-2025-02810

BBO-11818 in Adult Subjects With KRAS Mutant Cancer

AI 简述这是一项I期试验，研究BBO-11818用于KRAS突变实体瘤，在美国和澳大利亚开展。

?

适用疾病: Non-Small Cell Lung Cancer；NSCLC；PDAC - Pancreatic Ductal Adenocarcinoma
干预: BBO-11818，Pembrolizumab，Platinum chemotherapy (cisplatin or carboplatin)，Pemetrexed
地点: United States，Australia
申办方: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

正在招募阶段未标明放疗

ClinicalTrials.gov / NCI NCT06984562 / NCI-2025-05187

Adaptive Radiation for Locally Advanced Unresectable Pancreatic Cancer

AI 简述这是一项适应性放疗试验，用于局部晚期不可切除胰腺癌。

?

适用疾病: Locally Advanced Pancreatic Ductal Adenocarcinoma (PDA)；Stage II Pancreatic Cancer；Stage III Pancreatic Cancer
干预: Adaptive Radiation Therapy
地点: United States
申办方: Fox Chase Cancer Center

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06999187 / NCI-2025-07429

A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

AI 简述这是一项I期试验，研究DR-0202用于晚期复发难治性癌，在美国开展。

?

适用疾病: Triple Negative Breast Cancer；HER2-negative Breast Cancer；Non Small Cell Lung Cancer
干预: DR-0202
地点: United States
申办方: Dren Bio

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT07021066 / NCI-2025-07108

Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors

AI 简述这是一项I期试验，研究BL-M05D1用于晚期实体瘤，在美国开展。

?

适用疾病: Gastric Adenocarcinoma；Advanced Pancreatic Ductal Adenocarcinoma；Esophageal Adenocarcinoma
干预: BL-M05D1
地点: United States
申办方: SystImmune Inc.

正在招募阶段未标明手术/操作

ClinicalTrials.gov NCT07022015

Predictive Risk Factors for Pancreatic Fistula After Pancreaticoduodenectomy

AI 简述这是一项观察性研究，评估胰十二指肠切除术后胰瘘的预测风险因素，在埃及开展。

?

适用疾病: Pancreas Cancer；Pancreas Neoplasm；Pancreatic Fistula
干预: pancreaticoduodenectomy procedure
地点: Egypt
申办方: Minia University

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT07024615 / NCI-2025-05779

A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer

AI 简述这是一项I期试验，研究ASP2138术前给予，术后化疗用于可切除胰腺导管腺癌，在美国开展。

?

适用疾病: Pancreatic Ductal Adenocarcinoma；Stage I Pancreatic Cancer；Resectable Pancreatic Adenocarcinoma
干预: ASP2138，Oxaliplatin，Leucovorin，5-FU
地点: United States
申办方: Astellas Pharma Global Development, Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT07030283 / NCI-2025-05456

Intraperitoneal Paclitaxel With NALIRIFOX for Pancreatic Ductal Adenocarcinoma With Peritoneal Carcinomatosis

AI 简述这是一项1期试验，研究腹腔内紫杉醇联合NALIRIFOX用于胰腺导管腺癌伴腹膜癌。

?

适用疾病: Pancreatic Ductal Adenocarcinoma (PDAC)；Locally Advanced Pancreatic Ductal Adenocarcinoma；Resectable Pancreatic Ductal Adenocarcinoma
干预: Paclitaxel，NALIRIFOX
地点: United States
申办方: University of Colorado, Denver

正在招募 EARLY / Phase 1 药物手术/操作

ClinicalTrials.gov / NCI NCT07089940 / NCI-2025-05087

OMO-103 for the Treatment of Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma

AI 简述这是一项早期I期试验，研究OMO-103用于局部晚期或转移性胰腺导管腺癌，在美国开展。

?

适用疾病: Locally Advanced Pancreatic Ductal Adenocarcinoma；Metastatic Pancreatic Ductal Adenocarcinoma；Stage II Pancreatic Cancer AJCC v8
干预: Biopsy Procedure，Biospecimen Collection，Computed Tomography，Magnetic Resonance Imaging
地点: United States
申办方: OHSU Knight Cancer Institute

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT07090499 / NCI-2025-07625

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

AI 简述这是一项I期试验，研究PF-08046876用于晚期实体瘤，在美国、加拿大等地开展。

?

适用疾病: Advanced/Metastatic Solid Tumors；Bladder Cancer；Urothelial Carcinoma
干预: PF-08046876
地点: United States，Canada，Puerto Rico，Spain 等 1 个
申办方: Pfizer

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT07094204 / NCI-2025-06344

A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors

AI 简述这是一项I期试验，研究ASP5834用于实体瘤，在美国、法国等地开展。

?

适用疾病: Solid Tumor；Non-Small-Cell Lung Cancer；Pancreatic Ductal Adenocarcinoma
干预: ASP5834，panitumumab
地点: United States，France，Japan，Spain
申办方: Astellas Pharma Inc

正在招募阶段未标明手术/操作

ClinicalTrials.gov NCT07148830

Mesopancreatic Excision for Pancreatic Duct Adenocarcinoma.

AI 简述这是一项试验，评估全胰系膜切除术用于胰腺导管腺癌。

?

适用疾病: Pancreatic Ductal Adenocarcinoma；Pancreatic Cancer
干预: Total Mesopancreas Excision (TMpE) (as part of Pancreaticoduodenectomy)
地点: Egypt
申办方: Minia University

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT07165132 / NCI-2025-07443

Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.

AI 简述这是一项I期试验，研究RYZ401用于表达SSTR的实体瘤，在美国、加拿大等地开展。

?

适用疾病: GEP-NET；Gastroenteropancreatic Neuroendocrine Tumor；Gastroenteropancreatic Neuroendocrine Tumor Disease
干预: RYZ401
地点: United States，Canada
申办方: RayzeBio, Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT07189195 / NCI-2025-06181

TR-002 for the Treatment of Advanced, Unresectable or Metastatic Solid Tumors and Unresectable or Metastatic, Refractory Pancreatic Adenocarcinoma

AI 简述这是一项I期试验，研究TR-002用于晚期不可切除或转移性实体瘤和胰腺腺癌。

?

适用疾病: Advanced Malignant Solid Neoplasm；Metastatic Malignant Solid Neoplasm；Metastatic Pancreatic Adenocarcinoma
干预: TR-002
地点: United States
申办方: University of California, Davis

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT07227168 / NCI-2026-01753

A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer

AI 简述这是一项I期试验，研究STRO-004联合Pembrolizumab用于难治性/复发性转移性实体瘤，在美国开展。

?

适用疾病: Head and Neck Squamous Cell Carcinoma HNSCC；Non-Small Cell Lung Cancer NSCLC；Esophageal Cancer
干预: STRO-004，Pembrolizumab
地点: United States
申办方: Sutro Biopharma, Inc.

正在招募阶段未标明手术/操作

ClinicalTrials.gov NCT07232810

Prognostic Outcomes of Total Mesopancreas Excision for Pancreatic Head Cancer

AI 简述这是一项观察性研究，评估全胰周系膜切除对胰头癌的预后影响。在埃及开展。

?

适用疾病: Pancreatic Head Cancer；Pancreatic Ductal Adenocarcinoma
干预: Total Mesopancreas Excision (TMpE)
地点: Egypt
申办方: Minia University

正在招募 Phase 1 药物

ClinicalTrials.gov NCT07261631

Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors

AI 简述这是一项I期试验，研究[177Lu]Lu-DFC413用于多种实体瘤，在加拿大、丹麦、法国、德国等地开展。

?

适用疾病: Pancreatic Ductal Adenocarcinoma；Non-Small Cell Lung Cancer；HR+/HER2- Ductal and Lobular Breast Cancer
干预: 68Ga-NNS309，177Lu-DFC413
地点: Canada，Denmark，France，Germany 等 2 个
申办方: Novartis Pharmaceuticals

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT07277413 / NCI-2026-03872

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

AI 简述这是一项I期试验，研究IDE892单药或联合IDE397用于MTAP缺失的晚期实体瘤，在美国开展。

?

适用疾病: NSCLC Adenocarcinoma；Gastroesophageal Cancer (GC)；Gastric Adenocarcinoma
干预: IDE892，IDE397
地点: United States
申办方: IDEAYA Biosciences

正在招募 Phase 1 药物

ClinicalTrials.gov NCT07300150

A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors

AI 简述这是一项I期试验，研究PT0511联合西妥昔单抗用于KRAS突变或扩增的晚期实体瘤。

?

适用疾病: Colorectal Cancer；Pancreatic Cancer；Non-Small Cell Lung Cancer
干预: PT0511，Cetuximab
地点: United States，South Korea
申办方: PAQ Therapeutics, Inc.

正在招募阶段未标明手术/操作

ClinicalTrials.gov NCT07328607

Outcomes After Laparoscopic Versus Open Pancreaticoduodenectomy

AI 简述这是一项比较腹腔镜与开腹胰十二指肠切除术的试验，用于胰腺癌、壶腹癌、远端胆管癌等。

?

适用疾病: Pancreatic Ductal Adenocarcinoma；Ampullary Carcinoma；Distal Cholangiocarcinoma
干预: Open Pancreaticoduodenectomy，Laparoscopic Pancreaticoduodenectomy
地点: Egypt
申办方: Minia University

正在招募 Phase 1 药物

ClinicalTrials.gov NCT07349537

Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

AI 简述这是一项I期试验，研究RMC-5127用于KRAS G12V突变实体瘤，在美国开展。

?

适用疾病: Non-small Cell Lung Cancer (NSCLC)；Colorectal Cancer (CRC)；Pancreatic Adenocarcinoma
干预: RMC-5127，daraxonrasib，cetuximab
地点: United States
申办方: Revolution Medicines, Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov NCT07377045

Clinical Trial of OMTX705 in Combination With Gemcitabine/Nab-Paclitaxel and Tislelizumab in Patients With Advanced/Metastatic Pancreatic Adenocarcinoma

AI 简述这是一项I期试验，在美国和西班牙开展，研究OMTX705联合白蛋白紫杉醇/吉西他滨和替雷利珠单抗用于晚期/转移性胰腺腺癌。

?

适用疾病: Pancreatic Adenocarcinoma Metastatic
干预: OMTX705，Nab-paclitaxel + Gemcitabine，Tislelizumab (i.v. 200mg)
地点: United States，Spain
申办方: Oncomatryx Biopharma S.L.

正在招募 Phase 1 药物

ClinicalTrials.gov NCT07454642

AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors

AI 简述这是一项I期试验，研究AVA6103用于局部晚期或转移性实体瘤。

?

适用疾病: Vulvar Adenocarcinoma；PDAC - Pancreatic Ductal Adenocarcinoma；Gastric Adenocarcinoma
干预: AVA6103
地点: United States
申办方: Avacta Life Sciences Ltd

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT07458347 / NCI-2026-03309

A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation

AI 简述这是一项I期试验，研究KST-6051用于KRAS突变晚期实体瘤，包括非小细胞肺癌、胰腺癌、结直肠癌等。在美国开展。

?

适用疾病: KRAS-mutant Non-small Cell Lung Cancer (NSCLC)；KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC)；KRAS-mutant Colorectal Cancer (CRC)
干预: KST-6051
地点: United States
申办方: Kestrel Therapeutics, Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov NCT07481357

A First-In-Human Phase I/IIa Study to Evaluate DA 3501 in Patients With Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma and Pancreatic Ductal Adenocarcinoma

AI 简述这是一项I/IIa期试验，研究DA-3501用于晚期胃/胃食管结合部腺癌和胰腺癌。

?

适用疾病: Gastric (Stomach) Cancer；GastroEsophageal Cancer；Pancreatic Ductal Adenocarcinoma (mPDAC)
干预: DA-3501
地点: South Korea
申办方: Dong-A ST Co., Ltd.

正在招募 Phase 1 联合产品

ClinicalTrials.gov / NCI NCT07481383 / NCI-2026-02090

A First-in-Human Study to Evaluate Implantable Iontophoresis Chemotherapy Delivery Device With Gemcitabine Once Weekly or Twice Weekly in Participants With Pancreatic Cancer

AI 简述这是一项I期试验，研究植入式离子导入化疗装置（带吉西他滨）用于胰腺癌。

?

适用疾病: Pancreatic Adenocarcinoma Non-resectable；Stage III Pancreatic Cancer；Stage IV Pancreatic Cancer
干预: ACT Implantable Iontophoresis Chemotherapy Delivery Device with Gemcitabine (ACT-IOP-003)
地点: United States
申办方: Continuity Biosciences, LLC

正在招募 Phase 1 药物

ClinicalTrials.gov NCT07549958

PhIbRandomGemcitabine(G)w/or w/Out Pitavastatin(P)MainTx UnresecPancreaticAdenocarcinoma(uPDAC)

AI 简述这是一项1期试验，研究吉西他滨联合或不联合匹伐他汀用于不可切除胰腺腺癌。

?

适用疾病: Pancreatic Cancer；Pancreatic Cancer Metastatic
干预: Pitavastatin
地点: United States
申办方: University of California, Irvine

正在招募 Phase 1 生物制剂药物

ClinicalTrials.gov / NCI NCT07594067 / NCI-2026-04690

TCR1188-ABC Cells in KRAS-mutated Cancers

AI 简述这是一项I期试验，在美国开展，研究TCR1188-ABC细胞用于KRAS突变胆管癌、结直肠癌、非小细胞肺癌和胰腺癌。

?

适用疾病: Cholangiocarcinoma；Colorectal Cancer；Non-Small Cell Lung Cancer
干预: TCR1188-ABC cells，Fludarabine + Cyclophosphamide combination，Tocilizumab
地点: United States
申办方: University of Pennsylvania

正在招募阶段未标明手术/操作

ClinicalTrials.gov NCT07656571

Indocyanine Green-Guided Versus Standard Laparoscopic Distal Pancreatectomy for Pancreatic Body and Tail Lesions

AI 简述这是一项非分期试验，比较吲哚青绿引导与标准腹腔镜远端胰腺切除术用于胰腺体尾部病变，在埃及开展。

?

适用疾病: Pancreatic Neoplasms；Pancreatic Cancer
干预: ICG Fluorescence-Guided Laparoscopic Distal Pancreatectomy，Standard Laparoscopic Distal Pancreatectomy
地点: Egypt
申办方: Alexandria University

正在招募 Phase 1 药物

ClinicalTrials.gov NCT07671339

A Study of ELI-002 7P, With or Without Tislelizumab, in People With Pancreatic Cancer

AI 简述这是一项I期试验，研究ELI-002 7P联用或不联用替雷利珠单抗用于胰腺癌。在美国开展。

?

适用疾病: Pancreatic Cancer
干预: ELI-002 7P，Tislelizumab，mFOLFIRINOX
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 2

NCI NCT05773274 / NCI-2023-00118

Comparing Retreatment of 177Lu-DOTATATE PRRT versus the Usual Treatment in Patients with Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial

AI 简述这是一项II期试验，比较177Lu-DOTATATE PRRT再治疗与常规治疗用于转移性不可切除胃肠胰神经内分泌肿瘤，在美国和加拿大开展。

?

适用疾病: Metastatic Gastrointestinal Neuroendocrine Tumor G1；Metastatic Digestive System Neuroendocrine Tumor G2；Unresectable Digestive System Neuroendocrine Tumor G1
干预: 未列出
地点: United States，Canada
申办方: Canadian Cancer Trials Group

正在招募 Phase 1 药物手术/操作

ClinicalTrials.gov NCT03484299

Chemotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma

AI 简述这是一项I期试验，研究不可逆电穿孔联合化疗用于晚期胰腺腺癌。

?

适用疾病: Pancreas Cancer
干预: Irreversible Electroporation (IRE)，Gemcitabine，FOLFIRINOX
地点: United States
申办方: University of Louisville

正在招募 Phase 2 药物

ClinicalTrials.gov NCT04325425

Chemotherapy For Metastatic Grade 3 Poorly Differentiated NEuroendocrine Carcinoma Of GastroEnteroPancreatic And Unknown Primary

AI 简述这是一项II期试验，在法国开展，研究FOLFOXIRI联合化疗用于转移性胃肠胰神经内分泌癌。

?

适用疾病: Neuroendocrine Carcinoma
干预: FOLFOXIRI Protocol，Cisplatin injection
地点: France
申办方: Centre Hospitalier Universitaire Dijon

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT04911816

Neoadjuvant mFOLFIRINOX With Perioperative Oral Hydroxychloroquine in Resectable Pancreatic Adenocarcinoma

AI 简述这是一项I/II期试验，研究新辅助mFOLFIRINOX联合围手术期羟氯喹用于可切除胰腺腺癌。

?

适用疾病: Adenocarcinoma of the Pancreas
干预: Hydroxychloroquine sulfate
地点: United States
申办方: West Virginia University

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05821556

Valproic Acid/Simvastatin Plus Gemcitabine/Nab-paclitaxel Based Regimens in Untreated Metastatic Pancreatic Adenocarcinoma Patients

AI 简述这是一项II期试验，研究丙戊酸/辛伐他汀联合吉西他滨/白蛋白紫杉醇用于转移性胰腺腺癌。在意大利、西班牙等地开展。

?

适用疾病: Adenocarcinoma of the Pancreas
干预: Valproic acid，Simvastatin 20mg，Gemcitabine 1000 mg，Nab paclitaxel
地点: Italy，Spain
申办方: National Cancer Institute, Naples

正在招募 Phase 2 手术/操作

ClinicalTrials.gov NCT05984810

NIR-Fluorescence Guided Surgical Resection of Neoadjuvant Treated Localized Pancreatic Cancer Using SGM-101

AI 简述这是一项II期试验，研究SGM-101荧光引导手术用于新辅助治疗后的胰腺癌。

?

适用疾病: Pancreas Adenocarcinoma
干预: Fluorescence-guided surgery using CEA-targeted fluorophore SGM-101
地点: Netherlands
申办方: Leiden University Medical Center

正在招募阶段未标明手术/操作

ClinicalTrials.gov NCT06065891

Para-aortic Lymph Node Metastasis in Resectable Pancreatic Cancer

AI 简述这是一项观察性研究，评估腹主动脉旁淋巴结清扫用于可切除胰腺癌伴淋巴结转移。在丹麦、瑞典开展。

?

适用疾病: Pancreas Cancer；Pancreas Adenocarcinoma；Lymph Node Metastasis
干预: PALN resection
地点: Denmark，Sweden
申办方: Jon Unosson

正在招募阶段未标明手术/操作

ClinicalTrials.gov NCT06349278

Pancreatic Cancer and Synchronous Liver Metastases Resection Following Neoadjuvant FOLFIRINOX

AI 简述这是一项试验，研究FOLFIRINOX新辅助化疗后胰腺癌及同时性肝转移切除术。在加拿大开展。

?

适用疾病: Pancreas Adenocarcinoma；Pancreas Metastases；Pancreas Cancer
干预: Pancreatic resection and non-anatomic liver resections.
地点: Canada
申办方: Laval University

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06757244

DOVIPA, a Study Evaluating Efficacy and Safety of DOstarlimab and VItamin D3 With mFOLFIRINOX in PAncreatic Cancer

AI 简述这是一项II期试验，研究Dostarlimab联合维生素D3和化疗用于胰腺癌。

?

适用疾病: Pancreas Neoplasms
干预: Dostarlimab，Vitamin D3 (Cholecalciferol)，mFOLFIRINOX Treatment Regimen，LV5FU2
地点: France
申办方: Hopital Foch

正在招募 Phase 1 器械药物

ClinicalTrials.gov NCT07253662

Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Patients With Peritoneal Metastasis From Pancreatic Adenocarcinoma

AI 简述这是一项I期试验，在美国研究加压腹腔内气溶胶化疗（PIPAC）用于胰腺腺癌腹膜转移。

?

适用疾病: Adenocarcinoma Pancreas
干预: PIPAC，Nab-paclitaxel
地点: United States
申办方: Northwell Health

即将招募 Phase 3 药物

ClinicalTrials.gov NCT07620574

Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study

AI 简述这是一项III期长期扩展试验，用于既往参加过Exelixis研究的癌症患者，包括肾癌、胰腺神经内分泌肿瘤、肝细胞癌等。

?

适用疾病: Cancer；Renal Cell Carcinoma (RCC)；Pancreatic Neuroendocrine Tumors (pNET)
干预: Cabozantinib，Zanzalintinib，Atezolizumab，Nivolumab
地点: 未列出
申办方: Exelixis

即将招募 Phase 2, Phase 3 药物

ClinicalTrials.gov NCT07656376

Clinical Trial of DN022150 Combined With AG Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12D Mutation

AI 简述这是一项II/III期试验，研究DN022150联合AG化疗用于KRAS G12D突变局部晚期或转移性胰腺癌。

?

适用疾病: Pancreatic Cancer；Pancreatic Carcinoma
干预: DN022150+AG( Stage I ），DN022150+AG（Stage II），placebo+AG（Stage II）
地点: 未列出
申办方: Jiangxi Kvvit Pharmaceutical Co., Ltd.

即将招募 Phase 3 药物

ClinicalTrials.gov NCT07689539

Trial of DN022150 Versus Chemotherapy in Previously Treated Advanced Pancreatic Cancer With KRAS G12D Mutation

AI 简述这是一项III期试验，比较DN022150与化疗用于KRAS G12D突变的经治晚期胰腺癌。

?

适用疾病: Pancreatic Cancer
干预: DN022150，Chemotherapy
地点: 未列出
申办方: Jiangxi Kvvit Pharmaceutical Co., Ltd.

暂时不招募 Phase 1

NCI NCT03065062 / NCI-2017-00434

Palbociclib and Gedatolisib in Treating Patients with Advanced Solid Tumors or Lung, Pancreatic, or Head and Neck Cancer

AI 简述这是一项I期试验，研究Palbociclib和Gedatolisib用于晚期实体瘤或肺癌、胰腺癌、头颈癌。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Advanced Head and Neck Squamous Cell Cancer
干预: 未列出
地点: United States
申办方: Dana-Farber Harvard Cancer Center

暂时不招募 Phase 2

NCI NCT03074513 / NCI-2017-00501

Atezolizumab and Bevacizumab in Treating Patients with Rare Solid Tumors

AI 简述这是一项II期试验，研究Atezolizumab联合Bevacizumab用于罕见实体瘤。

?

适用疾病: Recurrent Merkel Cell Cancer；Malignant Solid Tumor；Stage III Nasopharyngeal Throat Cancer
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

暂时不招募 Phase 1, Phase 2

NCI NCT03919292 / NCI-2019-02675

Neratinib and Divalproex Sodium in Treating Patients with Advanced Solid Tumors or RAS-Mutated Cancers

AI 简述这是一项I/II期试验，研究Neratinib和Divalproex Sodium用于晚期实体瘤或RAS突变癌症，在美国开展。

?

适用疾病: Advanced Malignant Solid Tumor；Stage III Colon Cancer；Stage IV Colon Cancer
干预: 未列出
地点: United States
申办方: VCU Massey Comprehensive Cancer Center

暂时不招募 O

NCI NCT04975217 / NCI-2021-03484

Fecal Microbial Transplants for the Treatment of Pancreatic Cancer

AI 简述这是一项试验，研究粪便微生物移植用于胰腺导管腺癌，在美国开展。

?

适用疾病: Pancreatic Cancer；Pancreatic Ductal Adenocarcinoma
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

暂时不招募 Phase 1

NCI NCT05159050 / NCI-2022-03835

Paclitaxel-Loaded Tumor Penetrating Microparticles for the Treatment of Peritoneal Carcinomatosis

AI 简述这是一项I期试验，研究紫杉醇负载肿瘤穿透微粒用于腹膜癌。

?

适用疾病: Metastatic Malignant Solid Tumor；Metastatic Gastric Carcinoma；Metastatic Ovarian Carcinoma
干预: 未列出
地点: United States
申办方: University of Iowa/Holden Comprehensive Cancer Center

暂时不招募 Phase 1

NCI NCT05685602 / NCI-2022-08984

CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer

AI 简述这是一项I期试验，研究CA-4948联合标准化疗用于转移性或不可切除胰腺癌。

?

适用疾病: Stage III Pancreatic Cancer；Stage IV Pancreatic Cancer；Metastatic Pancreatic Ductal Adenocarcinoma
干预: 未列出
地点: United States
申办方: Yale University Cancer Center LAO

暂时不招募 Phase 2

NCI NCT05494697 / NCI-2023-02015

Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPC

AI 简述这是一项II期试验，研究Ampligen联合标准治疗用于局部晚期不可切除胰腺癌。

?

适用疾病: Stage II Pancreatic Cancer；Stage III Pancreatic Cancer；Stage IV Pancreatic Cancer
干预: 未列出
地点: United States
申办方: AIM ImmunoTech Inc.

暂时不招募 Phase 1, Phase 2

NCI NCT05922930 / NCI-2023-05027

Intraperitoneal TROP2-CAR-NK for the Treatment of Patients with Platinum-Resistant High Grade Ovarian Cancer, Mesonephric-Like Adenocarcinoma and Pancreatic Cancer

AI 简述这是一项I/II期试验，在美国研究腹腔内TROP2-CAR-NK治疗铂耐药卵巢癌、中肾管样腺癌和胰腺癌。

?

适用疾病: High Grade Ovarian Serous Adenocarcinoma；Primary Peritoneal High Grade Serous Adenocarcinoma；High Grade Fallopian Tube Serous Adenocarcinoma
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

暂时不招募 Phase 1

NCI NCT05958199 / NCI-2023-06569

A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7

AI 简述这是一项I期试验，研究NPX267用于表达HHLA2/B7-H7的实体瘤，在美国开展。

?

适用疾病: Malignant Solid Tumor；Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8；Stage IV Gastric (Stomach) Cancer
干预: 未列出
地点: United States
申办方: NextPoint Therapeutics, Inc.

即将招募 Phase 1 药物

ClinicalTrials.gov NCT06217666

Study Examining the Safety and Toxicity of Stereotactic Body Radiotherapy (SBRT) Followed by PCX12 Immunotherapy Delivered by Intratumoral Injection for the Treatment of Patients With Locally Advanced Pancreatic Adenocarcinoma (LAPC)

AI 简述这是一项I期试验，研究立体定向放疗后瘤内注射PCX-12用于局部晚期胰腺腺癌。

?

适用疾病: Pancreatic Adenocarcinoma
干预: PCX-12
地点: United States
申办方: Haoming (Carl) Qiu

即将招募阶段未标明放疗

ClinicalTrials.gov NCT06272162

Locally Advanced Pancreatic Cancer After Systemic Therapy: Ablative MR-guided Radiotherapy

AI 简述这是一项试验，研究MR引导放疗用于局部晚期胰腺癌。

?

适用疾病: Locally Advanced Pancreatic Adenocarcinoma
干预: MR guided radiotherapy
地点: Netherlands
申办方: UMC Utrecht

即将招募 Phase 1 药物

ClinicalTrials.gov NCT06549751

MT-601 Administered To Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer

AI 简述这是一项I期试验，研究MT-601用于局部晚期不可切除或转移性胰腺癌，在美国开展。

?

适用疾病: Pancreas Cancer；Pancreatic Cancer Metastatic；Pancreatic Cancer (Unresectable)
干预: MT-601 dose 200 million cells，MT-601 dose 400 million cells，MT-601 dose 800 million cells，MT-601 dose 1200 million cells
地点: United States
申办方: Marker Therapeutics, Inc.

即将招募 Phase 1 药物

ClinicalTrials.gov NCT06981806

Phase I Study of Cosibelimab and Balixafortide in Metastatic Pancreatic Ductal Adenocarcinoma

AI 简述这是一项I期试验，在美国研究Cosibelimab联合Balixafortide用于转移性胰腺导管腺癌。

?

适用疾病: Metastatic Pancreatic Ductal Adenocarcinoma
干预: Balixafortide，Balixafortide，Cosibelimab，Balixafortide
地点: United States
申办方: Arsen Osipov

即将招募阶段未标明器械手术/操作

ClinicalTrials.gov NCT07191418

Study-group on Palliative ERCP And RFA-ablation in Metastatic and Inoperable Pancreatic Tumors

AI 简述这是一项研究，在Sweden等地评估ERCP联合RFA消融用于肝转移的不可切除胰腺癌。

?

适用疾病: Pancreatic Cancer Metastatic to Liver
干预: Habib™ EndoHPB，ERCP
地点: Sweden
申办方: Roberto Valente

即将招募 Phase 1 器械药物

ClinicalTrials.gov NCT07314385

NH002-mediated Sonoporation With Chemotherapy in Advanced Pancreatic Cancer

AI 简述这是一项I期试验，研究NH002介导的声孔效应联合化疗用于晚期胰腺癌。

?

适用疾病: Pancreatic Adenocarcinoma Metastatic；Liver Metastasis
干预: nanoliposomal irinotecan+5-FU+leucovorin，NH002 (Perflutren Lipid Microspheres) Injectable Suspension，Aco Apache Ultrasound
地点: Taiwan
申办方: National Taiwan University Hospital

即将招募 Phase 1 药物

ClinicalTrials.gov NCT07348107

ATRA and SDK002 in Combination With Chemotherapy and Anti-PD-1 Inhibitor in Patients With Advanced Pancreatic Ductal Adenocarcinoma.

AI 简述这是一项I期试验，研究ATRA、三氧化二砷联合化疗和PD-1抑制剂用于晚期胰腺导管腺癌。

?

适用疾病: Advanced Pancreatic Ductal Adenocarcinoma
干预: ATRA，Arsenic Trioxide (ATO)，Gemcitabine，Nab-paclitaxel
地点: Canada
申办方: Daniel Breadner

即将招募阶段未标明手术/操作

ClinicalTrials.gov NCT07547033

Superior Mesenteric Artery First Versus Standard Approach in Pancreaticoduodenectomy

AI 简述这是一项外科试验，比较胰十二指肠切除术中优先处理肠系膜上动脉与标准入路用于胰腺头颈部腺癌。

?

适用疾病: Pancreatic Adenocarcinoma；Pancreatic Head Cancer
干预: SMA-first pancreaticoduodenectomy using either right posterior or anterior approach. SMA identified and isolated with peri-adventitial dissection before any irreversible section.，Conventional pancreaticoduodenectomy without prior isolation of the SMA; antero-posterior approach of the uncinate process after pancreatic section.
地点: France
申办方: Assistance Publique - Hôpitaux de Paris

即将招募 Phase 1 药物

ClinicalTrials.gov NCT07566897

A Phase I Study to Evaluate the Safety and Efficacy of L19IL2 in Combination With Ruxolitinib in Patients With Advanced Solid Tumors

AI 简述这是一项I期试验，研究L19IL2联合Ruxolitinib用于晚期实体瘤。

?

适用疾病: Renal Carcinoma Metastatic；Pancreatic Adenocarcinoma Metastatic；Pancreatic Adenocarcinoma
干预: L19IL2，Ruxolitinib
地点: Italy
申办方: Philogen S.p.A.

即将招募 Phase 1 生物制剂

ClinicalTrials.gov NCT07587827

Study Evaluating the Safety Feasibility and Efficacy of ODI-2001 Vaccine, a Personnalized Immunotherapy in Patients With Metastatic or Locally Advanced Colon Cancer or Pancreatic Cancer

AI 简述这是一项I期试验，在法国开展，研究个性化疫苗ODI-2001（包含DNA新抗原疫苗、MVA病毒载体和Ipilimumab）用于转移性或局部晚期结直肠癌或胰腺癌。

?

适用疾病: Metastatic Colorectal Cancer (CRC)；Locally Advanced Colorectal Cancer；Metastatic Pancreatic Cancer
干预: Personalized cancer vaccine including : DNA neoantigen vaccine, MVA viral vector and Ipilimumab (anti-CTLA4)
地点: France
申办方: Centre Georges Francois Leclerc

即将招募 Phase 1 生物制剂药物手术/操作

ClinicalTrials.gov NCT07619313

AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer

AI 简述这是一项I期试验，研究AB801联合化疗和免疫治疗用于交界可切除、局部晚期或转移性胆管癌或胰腺癌。

?

适用疾病: Borderline Resectable Pancreatic Ductal Adenocarcinoma；Locally Advanced Cholangiocarcinoma；Locally Advanced Pancreatic Adenocarcinoma
干预: Biopsy Procedure，Cisplatin，Computed Tomography，Durvalumab
地点: United States
申办方: Jonsson Comprehensive Cancer Center

即将招募 EARLY / Phase 1 药物

ClinicalTrials.gov NCT07627191

GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer

AI 简述这是一项早期I期试验，研究GLP-1受体激动剂（司美格鲁肽）联合标准治疗用于一线转移性胰腺癌、结直肠癌或肝细胞癌。

?

适用疾病: Pancreatic Cancer；Colorectal Cancer；Hepatocellular Carcinoma
干预: GLP1-RA (semaglutide)
地点: United States
申办方: University of Arizona

即将招募 Phase 1 药物手术/操作

ClinicalTrials.gov NCT07645651

Samuraciclib for the Treatment of Patients With Resectable, Borderline Resectable, or Locally Advanced Basal Pancreatic Cancer

AI 简述这是一项I期试验，研究Samuraciclib用于可切除或局部晚期基底型胰腺癌，在美国开展。

?

适用疾病: Resectable Pancreatic Ductal Adenocarcinoma；Borderline Resectable Pancreatic Ductal Adenocarcinoma；Locally Advanced Pancreatic Ductal Adenocarcinoma
干预: Samuraciclib，Computed Tomography，Endoscopic Ultrasound Biopsy，Biospecimen Collection
地点: United States
申办方: University of Washington

即将招募 Phase 1 药物

ClinicalTrials.gov NCT07650357

A Study of CLSP 5282 in HLA-A*03:01 Positive Adult Patients With Solid Tumors (SENTINEL-101)

AI 简述这是一项1期试验，研究CLSP-5282用于HLA-A*03:01阳性晚期实体瘤。在美国开展。

?

适用疾病: Advanced Solid Tumor；Non Small Cell Lung Cancer；Pancreatic Carcinoma
干预: CLSP-5282
地点: United States
申办方: Clasp Therapeutics, Inc.

即将招募 Phase 2 药物

ClinicalTrials.gov NCT03301805

A Phase II, EvaluateBLEX 404 Combined With Gemcitabine Monotherapy With Pancreatic Cancer

AI 简述这是一项II期试验，研究BLEX 404联合吉西他滨用于胰腺癌。

?

适用疾病: Pancreatic Cancer
干预: BLEX 404
地点: 未列出
申办方: Rgene Corporation

即将招募 Phase 2 药物

ClinicalTrials.gov NCT04901741

Olaptesed With Pembrolizumab and Nanoliposomal Irinotecan or Gemcitabine/Nab-Paclitaxel in MSS Pancreatic Cancer

AI 简述这是一项II期试验，研究Olaptesed联合Pembrolizumab和化疗用于微卫星稳定型转移性胰腺癌。

?

适用疾病: Metastatic Pancreatic Cancer
干预: Olaptesed pegol，Pembrolizumab
地点: 未列出
申办方: TME Pharma AG

即将招募 Phase 2 药物

ClinicalTrials.gov NCT05637567

Perioperative Platelet Inhibition With Acetylsalicylic Acid in Patients With Resectable Tumors of the Pancreatic Head

AI 简述这是一项II期试验，研究Acetylsalicylic acid用于可切除胰腺癌患者的围手术期治疗。

?

适用疾病: Pancreatic Cancer Resectable
干预: Acetylsalicylic acid，Placebo
地点: 未列出
申办方: German Cancer Research Center

即将招募 Phase 2 药物

ClinicalTrials.gov NCT05810792

Histamine Dihydrochloride and Interleukin-2 in Primary Resectable Pancreatic Cancer

AI 简述这是一项II期试验，研究组胺二盐酸盐联合IL-2用于可切除胰腺癌。

?

适用疾病: Pancreatic Cancer；Surgery；Metastasis
干预: Histamine Dihydrochloride (HDC)，Interleukin-2 (IL-2)
地点: 未列出
申办方: Sahlgrenska University Hospital

即将招募 Phase 1, Phase 2 药物放疗

ClinicalTrials.gov NCT06345599

PRaG Therapy in Combination With Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC) (NeoPRAG Study)

AI 简述这是一项I/II期试验，研究PRaG方案（放疗、免疫治疗、化疗）用于局部晚期胰腺导管腺癌。

?

适用疾病: Pancreatic Ductal Adenocarcinoma
干预: Radiotherapy，Immunotherapy:Granulocyte macrophage-colony stimulating factor(GM-CSF)、Cadumilimab，Chemotherapy:Albumin-bound paclitaxel、Gemcitabine
地点: 未列出
申办方: Second Affiliated Hospital of Soochow University

即将招募 Phase 2 联合产品

ClinicalTrials.gov NCT06573398

Radiotherapy With Sequential Chemotherapy Combined With PD-1 Inhibitor and Thymalfasin for BRPC

AI 简述这是一项II期试验，研究体部立体定向放疗序贯化疗联合PD-1抑制剂和胸腺法新用于交界可切除胰腺癌。

?

适用疾病: Carcinoma, Pancreatic Ductal
干预: SBRT with Sequential AG regimen +Tislelizumab+Thymalfasin
地点: 未列出
申办方: Ruijin Hospital

即将招募 Phase 1, Phase 2 生物制剂

ClinicalTrials.gov NCT07153289

CD318-targeted CAR-T Cell Therapy in Patients With Pancreatic Cancer (ResCPa)

AI 简述这是一项I/II期试验，研究CD318-CAR-T细胞用于胰腺导管癌。

?

适用疾病: Carcinoma, Pancreatic Ductal；Pancreatic Neoplasms
干预: CD318-CAR-T cells
地点: 未列出
申办方: University Hospital Tuebingen

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07230301

Adebrelimab Infusion Plus Standard Care for Pancreatic Cancer With Pleural or Peritoneal Effusions

AI 简述这是一项II期试验，研究Adebrelimab联合标准治疗用于伴有胸水或腹水的转移性胰腺癌。

?

适用疾病: Pancreatic Cancer Metastatic
干预: Adebrelimab (PD-L1 inhibitor)
地点: 未列出
申办方: Sizhen Wang

即将招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT07342725

Phase Ib/II Study to Evaluate the Safety and Efficacy of IBI363 in Combination With Chemotherapy as Second-Line Therapy for Unresectable Locally Advanced or Metastatic Pancreatic Cancer

AI 简述这是一项I/II期试验，研究IBI363联合化疗用于不可切除局部晚期或转移性胰腺癌的二线治疗。

?

适用疾病: Pancreatic Cancer Metastatic
干预: IBI363 + chemotherapy
地点: 未列出
申办方: Ruijin Hospital

即将招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT07435038

Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

AI 简述这是一项I/II期试验，研究BPI-572270用于RAS突变晚期实体瘤，包括非小细胞肺癌、结直肠癌等。

?

适用疾病: Non-small Cell Lung Cancer (NSCLC)；Colorectal Cancer (CRC)；Pancreatic Ductal Adenocarcinoma (PDAC)
干预: BPI-572270
地点: 未列出
申办方: Betta Pharmaceuticals Co., Ltd.

即将招募 Phase 1, Phase 2 生物制剂药物

ClinicalTrials.gov NCT07444541

ANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer

AI 简述这是一项I/II期试验，研究ANO31905联合化疗用于CLDN18.2阳性胰腺癌。

?

适用疾病: Pancreatic Cancer
干预: ANO31905，ANO31905，Nanoparticle Albumin-Bound Paclitaxel，Gemcitabine
地点: 未列出
申办方: Anova Innovation Limited

即将招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT07475234

Rimegepant Combined With AG Chemotherapy As First-Line Treatment For Metastatic Pancreatic Ductal Adenocarcinoma

AI 简述这是一项I/II期试验，研究Rimegepant联合AG化疗用于转移性胰腺导管腺癌一线治疗。

?

适用疾病: Metastatic Pancreatic Ductal Adenocarcinoma
干预: Rimegepant plus Nab-Paclitaxel and Gemcitabine
地点: 未列出
申办方: Xiuchao Wang

即将招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT07504263

Phase 1/2a Study of RP-001 in Participants With Advanced Malignancies

AI 简述这是一项I/IIa期试验，研究RP-001用于晚期恶性肿瘤。

?

适用疾病: Advanced Malignancies；Oncology；Colorectal Cancer
干预: RP-001
地点: 未列出
申办方: Recurv Pharma Inc

即将招募 Phase 1, Phase 2 生物制剂

ClinicalTrials.gov NCT07539155

Intratumoral MMR Vaccine Injection in Borderline Resectable/Unresectable Pancreatic Cancer

AI 简述这是一项I/II期试验，研究瘤内MMR疫苗注射用于可切除/不可切除胰腺癌。

?

适用疾病: Borderline Resectable/Unresectable Pancreatic Cancer；Non Metastatic Pancreatic Cancer
干预: Intratumoral MMR Injection
地点: 未列出
申办方: University of Arkansas

即将招募阶段未标明药物

ClinicalTrials.gov NCT07592819

A Trial Using Transcriptomic Signatures to Personalize Neoadjuvant Chemotherapy (NAC) for Patients With Resectable Borderline Pancreatic Adenocarcinoma (PDAC)

AI 简述这是一项试验，利用转录组特征个体化新辅助化疗（mFOLFIRINOX）用于可切除交界性胰腺腺癌。

?

适用疾病: Pancreas Adenocarcinoma (MSI-H)；Pancreatic Cancer Resectable
干预: mFOLFIRINOX (modified FOLFIRINOX)
地点: 未列出
申办方: Institut Paoli-Calmettes

即将招募 Phase 1, Phase 2 生物制剂药物手术/操作

ClinicalTrials.gov NCT07619521

Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a, for Advanced Pancreatic Ductal Adenocarcinoma

AI 简述这是一项I/II期试验，研究Selumetinib联合DS-8201a用于晚期胰腺导管腺癌。

?

适用疾病: Advanced Pancreatic Ductal Adenocarcinoma；Metastatic Pancreatic Ductal Adenocarcinoma；Stage III Pancreatic Cancer AJCC v8
干预: Biospecimen Collection，Diagnostic Imaging Testing，Echocardiography Test，Multigated Acquisition Scan
地点: 未列出
申办方: National Cancer Institute (NCI)

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07631884

Exploratory Study on the Efficacy and Safety of Trastuzumab Rezetecan in the Treatment of HER2-Expressiong Advanced Solid Tumor

AI 简述这是一项II期试验，研究Trastuzumab Rezetecan用于HER2表达晚期实体瘤。

?

适用疾病: Solid Tumors；Neoplasms (Cancer / Tumors)；Advanced Malignant Solid Neoplasm
干预: Trastuzumab Rezetecan
地点: 未列出
申办方: Haihua Yuan

术语	中文意思	对找临床试验有什么用
胰腺导管腺癌 / Pancreatic adenocarcinoma	最常见的胰腺癌病理类型。很多临床试验默认或明确针对这一类型。	搜索胰腺癌试验时，pancreatic adenocarcinoma 往往比 pancreatic cancer 更具体。
转移性胰腺癌 / Metastatic pancreatic cancer	癌症已经扩散到胰腺以外的远处部位，比如肝、腹膜、肺等。	很多试验会限定 metastatic 或 advanced 患者，需要结合影像报告确认。
晚期胰腺癌 / Advanced pancreatic cancer	通常指局部晚期或转移性疾病，具体定义要看试验入组标准。	可以作为 broad keyword 使用，再结合 metastatic、locally advanced 等词细化。
KRAS pancreatic cancer	KRAS 改变在胰腺癌中较常见，不同突变类型可能对应不同研究方向。	可以找 KRAS、KRAS G12D、KRAS G12V、pan-KRAS、RAS pathway 等相关试验。
BRCA pancreatic cancer	BRCA1/BRCA2 突变可能和 DNA 损伤修复通路有关，可能来自遗传或肿瘤检测。	可以找 PARP 抑制剂、DNA damage repair、platinum-sensitive 等相关试验。
FOLFIRINOX	胰腺癌中常见化疗组合之一，既往是否用过会影响部分试验的入组条件。	试验可能要求 previously treated with FOLFIRINOX，或排除不能耐受相关治疗的患者。
Gemcitabine	吉西他滨，是胰腺癌常见治疗药物之一，也常出现在联合治疗方案中。	可以找 gemcitabine-based therapy、after gemcitabine 等相关试验。
Second line	二线治疗，通常指一线治疗失败、进展或不能耐受后更换的下一套方案。	很多胰腺癌试验会限定既往用药和治疗线数，需要准备完整治疗记录。

Recruiting	正在招募，可能仍可申请参加。
Not yet recruiting	尚未开始招募，可关注后续开放时间。
Active, not recruiting	试验仍在进行，但通常不再招新患者。
Completed	试验已经完成。
Terminated	试验提前终止。
Unknown	公开页面上的状态不明确或未及时更新。

胰腺癌

当前同步到的治疗类试验